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Trifloxystrobin is one of the main active principles belonging to the strobilurin family of 23 
crop protection compounds. In this article, the synthesis of a battery of regioisomeric 24 
functionalized derivatives of trifloxystrobin is described. The same aliphatic linear 25 
carboxylated chain was introduced as spacer arm in all of the synthesized haptens, but it 26 
was located at different positions of the parent molecule. N,N’-Disuccinimidyl carbonate 27 
was employed for hapten activation, so the resulting N-hydroxysuccinimyl ester could be 28 
readily purified and efficiently coupled to proteins. After immunization and hybridoma 29 
generation, a collection of 20 mouse monoclonal antibodies from different immunizing 30 
haptens was obtained. The analytical performance of these immunoreagents was 31 
evaluated in terms of affinity and selectivity with the aim to develop rapid and practical 32 
immunochemical procedures for trifloxystrobin determination. 33 
  34 
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1. Introduction 35 
 Strobilurins are a new growing class of synthetic fungicide compounds that are 36 
used for plant protection. During the last five years, the number of registered strobilurins 37 
has doubled, revealing the great commercial success of these bioactive substances. 38 
Nowadays, one of the best sold strobilurins is trifloxystrobin (Bayer, 2010). Structurally, 39 
trifloxystrobin is characterized by a methyl (E)-2-(methoxyimino)-2-phenylacetate 40 
toxophore group and a trifluoromethylphenyl moiety linked by a 41 
(E)-ethylideneaminooxymethyl bridge (Fig. 1). Out of the four possible geometric isomers 42 
of the trifloxystrobin molecule (EE, EZ, ZE, and ZZ), the EE isomer is by far the most 43 
effective to combat fungal diseases. Accordingly, just the EE isomer is used in the 44 
commercial fungicide formulations and therefore it is the only residue sought in common 45 
pesticide monitoring programs (K. Banerjee, Ligon, & Spiteller, 2005). Like the other 46 
members of this family of fungicides, it is classified as QoI inhibitor, blocking mitochondrial 47 
respiration in fungi of the four main groups of plant pathogens, i.e., ascomycetes, 48 
basidiomycetes, deuteromycetes, and oomycetes (Balba, 2007; Bartlett, Clough, Godwin, 49 
Hall, Hamer, & Parr-Dobrzanski, 2002). Trifloxystrobin shows low toxicity to mammals, 50 
birds, bees, terrestrial organisms, and some plants, but it is highly noxious to fishes, 51 
aquatic organisms, and algae. Microbial metabolism primarily consists in hydrolysis of the 52 
methyl ester group (Kaushik Banerjee, Ligon, & Spiteller, 2006, 2007). 53 
 Immunochemical methods constitute alternative approaches for chemical residue 54 
analysis. The successful generation of specific antibodies and sensitive assays to a small 55 
organic molecule, such as a pesticide, is greatly dependent upon a proper design of 56 
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immunizing and assay haptens. Conformation and electronic features of the target 57 
compound should be mimicked by the immunizing hapten, and a proper display of its 58 
main characteristic chemical moieties as part of a protein conjugate has to be maximized  59 
(Mercader, Agullo, Abad-Somovilla, & Abad-Fuentes, 2011; Shan, Lipton, Gee, & 60 
Hammock, 2003). Consequently, hapten and protein are commonly linked through a 61 
spacer arm, which must show low immunogenicity and must not interfere with antibody 62 
binding. Most commonly, a linear aliphatic chain of 3 to 6 carbon atoms is employed as 63 
linker (Abad, Moreno, & Montoya, 1998; Y. J. Kim, Cho, Lee, Lee, Gee, & Hammock, 2003), 64 
though good results with shorter linkers have been reported (Kong, Zhang, Zhang, Gee, & 65 
Li, 2010; Suarez-Pantaleon, Mercader, Agullo, Abad-Somovilla, & Abad-Fuentes, 2008). In 66 
a previous article, antibodies to trifloxystrobin were produced from a single immunizing 67 
hapten without spacer arm (Mercader, Suarez-Pantaleon, Agullo, Abad-Somovilla, & Abad-68 
Fuentes, 2008a). However, trifloxystrobin is a very flexible molecule that can adopt many 69 
different energetically similar conformations – even in the crystalline solid state, it adopts 70 
two different conformations which appear mixed in the obtained X-ray structure (Ziegler, 71 
Benet-Buchholtz, Etzel, & Gayer, 2003). Due to this mobility, it is not easy to predict, not 72 
even using computer-assisted molecular modeling, which position of the molecular 73 
skeleton would be more suitable for incorporation of the spacer arm in order to prepare 74 
an immunizing conjugate with prolonged and advantageous display of the hapten to the 75 
immune system, thereby increasing the chance of producing antibodies with enhanced 76 
binding properties against the target analyte. In the present study, we report the rational 77 
design and synthesis of seven haptens with the only difference of linker positioning in the 78 
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trifloxystrobin framework, thus covering a great variety of possible spatial orientations of 79 
the molecule. The performance of the prepared regioisomeric molecules as immunogens 80 
was evaluated through the generation of mouse monoclonal antibodies (mAb). The novel 81 
collection of immunoreagents was characterized in the two main competitive enzyme-82 
linked immunosorbent assay (cELISA) formats, i.e., direct and indirect, and using 83 
homologous and heterologous conjugates. Moreover, trifloxystrobin structural analogues 84 
were synthesized and used as competitors in order to map epitope molecular interactions. 85 
In the following article of this series, the best combinations of antibody and conjugate 86 
were employed for immunoassay development, and subsequently for trifloxystrobin 87 
analysis in food samples. 88 
2. Materials and methods 89 
2.1. Chemicals and instrumentation 90 
Analytical grade trifloxystrobin (methyl (E)-methoxyimino-[(E)-α-[1-(α,α,α-91 
trifluoro-m-tolyl)ethylideneaminooxy]-o-tolyl]acetate) was kindly provided by Bayer 92 
CropScience (Frankfurt, Germany). Details about reagents, solvents, synthetic procedures, 93 
and techniques used in the structural characterization of synthesized compounds are 94 
described in the Supplementary Data File. Horseradish peroxidase (HRP), ovalbumin 95 
(OVA), Freund’s adjuvants, and o-phenylenediamine were purchased from Sigma/Aldrich 96 
(Madrid, Spain). Bovine serum albumin (BSA) fraction V was from Roche Applied Science 97 
(Mannheim, Germany). Sephadex G-25 HiTrap Desalting columns for protein–hapten 98 
conjugate purification and Sepharose HiTrap Protein G HP columns for antibody 99 
purification were obtained from GE Healthcare (Uppsala, Sweeden). Rabbit anti-mouse 100 
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immunoglobulin polyclonal antibody conjugated to peroxidase (RAM–HRP) was bought 101 
from Dako (Glostrup, Denmark). Immunoglobulin isotype was determined using the 102 
Mouse MonoAb-ID kit from Invitrogen (Carlsbad, CA, USA). Costar flat-bottom high-103 
binding 96-well polystyrene ELISA plates were from Corning (Corning, NY, USA). UV–visible 104 
spectra and ELISA absorbances were read with a PowerWave HT from BioTek Instruments 105 
(Winooski, VT, USA). Microwells were washed with an ELx405 microplate washer also 106 
from BioTek Instruments. 107 
2.2. Synthesis of haptens and active esters 108 
Seven functionalized regioisomeric haptens of trifloxystrobin with equivalent 109 
spacer arms located at different positions of the trifloxystrobin skeleton were synthesized 110 
(Fig. 1). Full experimental details and physical and spectroscopic data of all of the haptens 111 
and synthetic intermediates are provided in the Supplementary Data File (Fig. S1 to S6). 112 
Carboxylated haptens were activated by formation of the corresponding 113 
N-hydroxysuccinimidyl ester (NHS-ester) using N,N’-disuccinimidyl carbonate (DSC) and 114 
Et3N in dry acetonitrile as previously described (Esteve-Turrillas, Parra, Abad-Fuentes, 115 
Agullo, Abad-Somovilla, & Mercader, 2010). Briefly, the hapten (0.074 mmol) and DSC (25 116 
mg, 0.096 mmol) were dissolved in anhydrous acetonitrile (730 μL) under nitrogen in an 117 
ice-water bath. Et3N (40 μL, 0.281 mmol) was then added and the resulting mixture was 118 
stirred at room temperature until complete consumption of starting material (as observed 119 
by thin-layer chromatography). The reaction mixture was diluted with CHCl3, washed with 120 
a 10% aqueous solution of NaHCO3 and brine, and dried over anhydrous Na2SO4. The 121 
residue obtained after evaporation of the solvent was purified by column 122 
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chromatography, using CHCl3 as eluent, affording the NHS-esters in good yield (60-95%) 123 
and in highly pure form, as shown by 1H NMR spectroscopy (copies of original spectra are 124 
included in the Supplementary Data File). 125 
TFa-NHS ester: 86% yield. 1H-NMR (300 MHz)  (ppm) 7.87 (1H, br s, H-2’’), 7.78 126 
(1H, d, J = 7.8 Hz, H-6’’), 7.59 (1H, br d, J = 7.8 HZ, H-4’’), 7.46 (1H, br t, J = 7.8 Hz, H-5’’), 127 
7.29 (1H, br s, H-2’), 7.20 (1H, dd, J = 7.8, 1.6 Hz, H-6’), 7.11 (1H, d, J = 7.8 Hz, H-5’), 5.12 128 
(2H, s, OCH2), 4.03 (3H, s, NOCH3), 3.81 (3H, s, CO2CH3), 2.83 (4H, br s, COCH2CH2CO), 2.67 129 
(2H, t, J = 7.5 Hz, H-6), 2.60 (2H, t, J = 7.4 Hz, H-2), 2.22 (3H, s, CH3), 1.83–1.65 (4H, m, H-3 130 
and H-5), 1.49 (2H, m, H-4). 131 
TFb-NHS ester: 80% yield. 1H-NMR (300 MHz)  (ppm) 7.67 (1H, br s, H-4’), 7.59 132 
(1H, br s, H-2’), 7.51 (1H, dd, J = 7.6, 1.5 Hz, H-3’’), 7.46–7.36 (3H, m, H-5’’, H-6’ and H-4’’), 133 
7.19 (1H, dd, J = 7.4, 1.5 Hz, H-6’’), 5.14 (2H, s, OCH2), 4.03 (3H, s, NOCH3), 3.82 (3H, s, 134 
CO2CH3), 2.83 (4H, br s, COCH2CH2CO), 2.66 (2H, t, J = 7.3 Hz, H-2), 2.62 (2H, t, J = 7.4 Hz, 135 
H-6), 2.21 (3H, s, CH3), 1.79 and 1.67 (2H each, each m, H-3 and H-5), 1.47 (2H, m, H-4). 136 
TFc-NHS ester: 60% yield. 1H-NMR (300 MHz)  (ppm) 7.85 (1H, br s, H-2’’), 7.75 137 
(1H, d, J = 7.8 Hz, H-6’’), 7.59 (1H, d, J = 7.8 Hz, H-4’’), 7.51–7.35 (4H, m, H-3’, H-4’, H-5’, 138 
and H-5’’), 7.18 (1H, dd, J = 7.5, 1.3 Hz, H-6’), 5.11 (2H, s, OCH2), 4.03 (3H, s, NOCH3), 3.81 139 
(3H, s, CO2CH3), 2.82 (4H, br s, COCH2CH2CO), 2.75 (2H, t, J = 7.9 Hz, H-6), 2.55 (2H, t, J = 140 
7.4 Hz, H-2), 1.73 (2H, quint, J = 7.5 Hz, H-3), 1.56–1.42 (4H, m, H-4 and H-5). 141 
TFe-NHS ester: 84% yield. 1H-NMR (300 MHz)  (ppm) 7.86 (1H, br s, H-2’’), 7.80 142 
(1H, d, J = 7.8 Hz, H-6’’), 7.59 (1H, d, J = 7.8 Hz, H-4’’), 7.48 (1H, m, H-6’), 7.46 (1H, m, H-143 
5’’), 7.42 (1H, m, H-5’), 7.37 (1H, m, H-4’), 7.18 (1H, dd, J = 7.3, 1.5 Hz, H-3’), 5.14 (2H, s, 144 
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OCH2), 4.21 (2H, t, J = 6.7 Hz, H-6), 4.02 (3H, s, NOCH3), 2.82 (4H, br s, COCH2CH2CO), 2.53 145 
(2H, t, J = 7.3 Hz, H-2), 2.23 (3H, s, CH3), 1.73–1.59 (4H, m, H-3 and H-5), 1.44–1.28 (2H, m 146 
,H-4). 147 
TFo-NHS ester: 95% yield. 1H-NMR (300 MHz)  (ppm) 7.85 (1H, br s, H-2’’), 7.79 148 
(1H, d, J = 7.9 Hz, H-6’’), 7.59 (1H, d, J = 7.8 Hz, H-4’’), 7.48 (1H, m, H-6’), 7.46 (1H, m, H-149 
5’’), 7.42 (1H, m, H-5’), 7.37 (1H, m, H-4’), 7.18 (1H, dd, J = 7.3, 1.5 Hz, H-3’), 5.14 (2H, s, 150 
OCH2), 4.25 (2H, t, J = 6.7 Hz, H-6), 3.81 (3H, s, CO2CH3), 2.82 (4H, br s, COCH2CH2CO), 2.52 151 
(2H, t, J = 7.4 Hz, H-2), 2.22 (3H, s, CH3), 1.68 (4H, m, H-3 and H-5), 1.38 (2H, m, H-4). 152 
TFf-NHS ester: 88% yield. 1H-NMR (300 MHz)  (ppm) 7.51 (1H, dd, J = 7.4, 1.3 Hz, 153 
H-3’’), 7.45–7.34 (4H, m, H-2’, H-4’, H-4’’ and H-5’’), 7.25 (1H, t, J = 7.7 Hz, H-5’), 7.22–154 
7.14 (2H, m, H-6’’ and H-6’), 5.12 (2H, s, OCH2), 4.03 (3H, s, NOCH3), 3.81 (3H, s, CO2CH3), 155 
2.82 (4H, br s, COCH2CH2CO), 2.65-2.58 (2H, two overlapped t, J = 7.5 Hz, H-2 and H-6), 156 
2.20 (3H, s, CH3), 1.83–1.61 (4H, m, H-3 and H-5), 1.50–1.41 (2H, m, H-4). 157 
TFt-NHS ester: 75% yield. 1H-NMR (300 MHz)  (ppm) 7.62 (1H, t, J = 1.5 Hz, H-2’), 158 
7.57–7.47 (2H, m, H-6’ and H-3’’), 7.46–7.33 (3H, m, H-5’’, H-4’’ and H-4’), 7.25 (1H, t, J = 159 
7.8 Hz, H-5’), 7.18 (1H, dd, J = 7.4, 1.4 Hz, H-6’’), 5.12 (2H, s, OCH2), 4.03 (3H, s, NOCH3), 160 
3.82 (3H, s, CO2CH3), 2.84 (4H, br s, COCH2CH2CO), 2.82 (2H, t, J = 7.4 Hz, H-4), 2.58 (2H, t, 161 
J = 7.0 Hz, H-2), 2.18 (3H, s, CH3), 2.06 (2H, quint, J = 7.2 Hz, H-3). 162 
2.3. Synthesis of analogues 163 
A small collection of trifloxystrobin analogues was synthesized, each one 164 
possessing a single structural modification of the trifloxystrobin molecule (Table 1). With 165 
the exception of TFa-I, an intermediate in the synthesis of hapten TFa, the rest of the 166 
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analogues were prepared ex novo from readily available materials via the same type of 167 
strategy used for the preparation of the hapten framework, which was based on the 168 
O-alkylation reaction of a conveniently functionalized oxime with the appropriated 169 
bromo-benzyl derivative. A complete description of the preparation of these analogues is 170 
provided in the Supplementary Data File (Fig. S7). 171 
2.4. Conjugate preparation 172 
Conjugation was carried out with 1, 5, and 10 µmol of activated hapten 173 
(hapten-NHS ester) and HRP (2.2 mg), OVA (30 mg), and BSA (15 mg), respectively, in 174 
50 mM carbonate buffer, pH 9.6. For details see Mercader et al. (Mercader, Esteve-175 
Turrillas, Agullo, Abad-Somovilla, & Abad-Fuentes, 2012). Protein–hapten conjugates were 176 
purified by gel filtration using 100 mM phosphate buffer, pH 7.4 as eluent, and stored 177 
frozen at −20 °C. Coupling degrees were calculated at 280 nm from absorbance values 178 
before and after conjugation.  179 
2.5. Antibody production 180 
Animal manipulation was carried out in compliance with Spanish laws and 181 
guidelines (RD1201/2005 and law 32/2007) and according to European Directive 182 
2010/63EU concerning protection of animals used for scientific purposes. Each BSA 183 
conjugate was used to immunize a set of female BALB/c mice with 0.1 mg of conjugate per 184 
animal. Immunogen emulsions were prepared with BSA conjugates in sterile PBS (10 mM 185 
phosphate, pH 7.4 containing 140 mM NaCl) and Freund’s adjuvant. Regular immunization 186 
schedules were followed as previously described (Parra, Mercader, Agullo, Abad-187 
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Somovilla, & Abad-Fuentes, 2012). Ten days after the third injection, a blood sample was 188 
taken by submandibular bleeding. For hybridoma generation, a standard cell fusion 189 
protocol was followed and cells were distributed in 96-well culture microplates 190 
(Mercader, Suarez-Pantaleon, Agullo, Abad-Somovilla, & Abad-Fuentes, 2008a). Selection 191 
of the best hybridomas was carried out by a double screening process (Mercader, Suarez-192 
Pantaleon, Agullo, Abad-Somovilla, & Abad-Fuentes, 2008b). Briefly, a differential ELISA 193 
was performed with the supernatant of every microwell by parallel evaluation of a control 194 
well without competitor and a test well with 100 nM trifloxystrobin. Next, those 195 
supernatants exhibiting a clearly lower signal in the test well than in the control well were 196 
reevaluated by a checkerboard competitive screening test, in which diverse trifloxystrobin 197 
concentrations (0, 10, and 100 nM) were tested with serial dilutions of culture 198 
supernatant and different coating concentrations of homologous conjugate. Supernatants 199 
affording saturated signals in the control well were also included in this analysis. 200 
Hybridomas were cloned twice by limiting dilution. Antibodies were purified from 100–201 
150 mL culture supernatants by affinity chromatography, and stored at 4 °C as ammonium 202 
sulfate precipitates. 203 
2.6. Competitive ELISAs 204 
 Immunoassays were carried out at room temperature using two different formats: 205 
the antibody-coated direct cELISA and the conjugate-coated indirect cELISA. Briefly, plates 206 
were coated by overnight incubation at room temperature with immunoreagent solution 207 
in 50 mM carbonate buffer, pH 9.6. For direct assays, coating was done with 100 µL per 208 
well of antibody solution, and after washing the competitive step was performed during 209 
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1 h with 50 µL per well of trifloxystrobin standard solution in PBS and 50 µL per well of 210 
enzyme tracer dilution in PBST (PBS containing 0.05% (v/v) Tween 20). Indirect 211 
competitive assays were developed in OVA conjugate-coated plates using 50 µL per well 212 
of analyte solution in PBS and 50 µL per well of primary antibody dilution in PBST. For 213 
detection, 100 µL per well of RAM–HRP (diluted 1/2000 in PBST) was used. Both, the 214 
competitive and the secondary reaction were brought to equilibrium by incubation during 215 
1 h. Plates were washed four times after each step and signal was generated using a 216 
freshly prepared 0.012% (v/v) H2O2 solution in 25 mM citrate and 62 mM phosphate 217 
buffer, pH 5.4 containing 2 mg mL−1 o-phenylendiamine. The enzymatic activity was 218 
stopped after 10 min with 2.5 M sulfuric acid. Absorbance was read at 492 nm with a 219 
reference wavelength at 650 nm. 220 
2.7. Inhibition curves and data analysis 221 
Starting from a 10 µM trifloxystrobin solution in PBS, standard curves were prepared 222 
by 10-fold serial dilution in the same buffer. A 10 mM trifloxystrobin stock solution in 223 
anhydrous N,N-dimethylformamide was used to prepare the first standard point. 224 
Experimental values were fitted to a four-parameter logistic equation using the SigmaPlot 225 
software package from SPSS Inc. (Chicago, IL, USA). Antibody affinity was estimated as the 226 
trifloxystrobin concentration at the midpoint of the sigmoidal curve, usually refers to as 227 
IC50. Cross-reactivity (CR) was calculated as percentage value from the quotient between 228 
the IC50 for trifloxystrobin and the IC50 for the studied analogous compound, both in molar 229 
concentration units.  230 
  231 
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3. Results and discussion 232 
3.1. Preparation of haptens and active esters 233 
A battery of regioisomeric haptens of trifloxystrobin covering the entire molecular 234 
framework was prepared (Fig. 1B). All of the haptens maintained the structure and main 235 
functional groups of the parent molecule, introducing the minimum possible 236 
conformational and electronic changes, with the linker located at a variety of positions. In 237 
all cases, the spacer arm was a C-6 saturated hydrocarbon chain, with the exception of 238 
TFt, which was functionalized through the same attachment site that TFf and was 239 
synthesized to assess whether the introduction of a triple bond in the linker may 240 
contribute, through rigidity effects, to an improved hapten exposure. 241 
Hapten TFe was prepared directly from trifloxystrobin in three steps via hydrolysis 242 
of the methyl ester moiety followed by O-alkylation of the carboxylate group with 243 
tert-butyl 6-bromohexanoate and acid hydrolysis of the tert-butyl ester group (see Fig. S4 244 
and experimental details in the Supplementary Data file). The rest of the haptens were 245 
obtained by total synthesis from commercially available starting materials. The synthetic 246 
strategy that was followed for their preparation was based on the Williamson-type 247 
O-alkylation reaction of a conveniently functionalized oxime, which provided the 248 
(1-oxyiminoalkyl)phenyl substructural moiety (left-hand side of the hapten planar 249 
structure in Fig. 1B), with the appropriate benzyl bromide, which supplied the methyl 250 
2-(alkoxyimino)-2-(o-tolyl)acetate subunit (right-hand side of the structure in Fig. 1B). 251 
Incorporation of the alkyl C-6 carboxylated spacer arm was accomplished either through a 252 
palladium catalyzed Sonogashira cross-coupling reaction with tert-butyl hex-5-ynoate and 253 
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hydrogenation of the triple bond, or by means of an alkylation reaction with the 254 
corresponding tert-butyl bromoester. In all cases, the synthesis was completed by acid 255 
hydrolysis of the tert-butyl ester moiety. 256 
As illustrated in Fig. 2A, the synthesis of haptens TFa and TFo implied the 257 
O-alkylation reaction of oxime i – prepared according to the procedure described in the 258 
literature by Neufeldt et al. (Neufeldt & Sanford, 2010) – and a benzyl bromide such as ii, 259 
whose preparation was carried out from readily available tolyl derivatives following 260 
previously reported methodology (Itoh, Nagata, Nomura, Takanaga, Sugita, & Ichikawa, 261 
1984; Wenderoth, Sauter, Wingert, Hepp, Brand, Kuekenhoehner, et al., 1990). The 262 
incorporation of the C-6 carboxylated spacer arm was realized by means of an O-alkylation 263 
reaction of a hydroxyimino group, in the case of hapten TFo, and a palladium catalyzed 264 
Sonogashira cross-coupling reaction followed by hydrogenation of a triple bond, in the 265 
case of hapten TFa.  266 
The synthesis of haptens TFb and TFc involved, as the key step, the O-alkylation 267 
reaction of an oxime such as iii or iv, respectively, with benzyl bromide v, which was 268 
obtained following a modification of the literature procedures from commercial 269 
1-(o-tolyl)ethanone (Hwang, Kim, Kim, & Kyung, 2009; J.-K. Kim, Kim, Hwang, & Nam, 270 
2009; Wenderoth, Sauter, Wingert, Hepp, Brand, Kuekenhoehner, et al., 1992)(Fig. 2B). 271 
For hapten TFb, the preparation of the intermediate oxime involved bromination of the 272 
phenyl ring of 3-(trifluoromethyl)benzoic acid and transformation of the carboxylic group 273 
into a methyl ketone group, followed by incorporation of the carboxylated alkyl chain 274 
through a Sonogashira cross-coupling reaction, hydrogenation of the triple bond, and 275 
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condensation of the carbonyl ketone group with hydroxylamine. On the other hand, the 276 
oxime that was needed for the preparation of hapten TFc was synthesized from 277 
1-(3-(trifluoromethyl)phenyl)ethanone through α-alkylation to the carbonyl group with 278 
tert-butyl 5-bromopentanoate followed by oxime formation. The first transformation did 279 
not take place by direct alkylation of the enolate derived from the methyl ketone group, 280 
so it was necessary to use an indirect alkylation process, based on the temporal 281 
transformation of the methyl ketone group into the corresponding allyl β-keto ester 282 
derivative (Paulvannan & Chen, 1999; Snider & Buckman, 1992). 283 
 Finally, haptens TFf and TFt were synthesized through the same synthetic 284 
sequence, similar to that described above for hapten TFb, starting from 285 
1-(3-bromophenyl)ethanone (Fig. 2C). After preparation of the required key oxime vi, 286 
O-alkylation with benzyl bromide iv and acid hydrolysis of the tert-butyl ester led to 287 
hapten TFt. On the other hand, hydrogenation of the triple bond previously to hydrolysis 288 
of the tert-butyl ester group afforded hapten TFf.  289 
In order to allow coupling to carrier proteins, the carboxylic acid group of the 290 
haptens was activated through formation of the corresponding N-succinimidyl ester (see 291 
Fig. 1 for structure of the corresponding NHS-esters). This was readily performed using 292 
DSC as activating reagent. This activation procedure is highly efficient giving exclusively 293 
CO2 and N-hydroxysuccinimide as the only by-products, which allowed an easy purification 294 
of the intended active esters. 295 
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3.2. Preparation of hapten–protein conjugates 296 
The availability of the activated haptens in the purified form allowed us to readily 297 
prepare both the immunizing and the assay conjugates using the same coupling procedure 298 
and with a good control of the hapten-to-protein molar ratio (MR). A set of BSA, OVA, and 299 
HRP conjugates for every hapten was obtained with high yields. Calculated hapten-to-300 
protein MRs were between 8 and 22, 3 and 5, and 3 and 7 for BSA, OVA, and HRP 301 
conjugates, respectively. MRs of BSA and OVA conjugates were in the usual range, 302 
whereas the unlikely estimated values that were observed with some of the HRP 303 
conjugates were probably due to modified molar extinction coefficients of the protein 304 
and/or the hapten after conjugation. 305 
3.3. Antibody affinity 306 
 A collection of mAbs to trifloxystrobin was generated using BSA conjugates of all of 307 
the synthesized regioisomeric haptens. A set of 4 mice was immunized with each 308 
conjugate, and positive immune response was confirmed with a small serum sample that 309 
was obtained 10 days after the third injection. Cell fusions were carried out with all of the 310 
mice with mostly high efficiencies for hybrid cell formation. Spleens were processed 311 
individually or several spleens from the same set of animals were pooled. A summary of 312 
cell fusion results can be found in Table S1 of the Supplementary Data File. Immunogen 313 
BSA–TFa afforded the lowest number (1.2%) of positive clones – clones segregating 314 
antibodies that recognized the immobilized conjugate –, whereas conjugate BSA–TFt gave 315 
the highest amount of positive clones (60.7%). Further work with other analytes and 316 
haptens is required to conclusively ascribe this high ratio of positive clones to the 317 
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presence of a triple bond in the spacer arm of hapten Tft. The employed double screening 318 
process using a differential and a checkerboard approach, as previously described 319 
(Mercader, Suarez-Pantaleon, Agullo, Abad-Somovilla, & Abad-Fuentes, 2008b), allowed 320 
identification of those clones producing antibodies that bound free trifloxystrobin with 321 
high affinity. Following that process, a total of 20 hybridomas were generated and 322 
stabilized – at least two hybridomas were cloned from each set of immunized animals. All 323 
antibodies were constituted by κ light chains and were of the IgG1 isotype, except 324 
antibodies TFt#35 and TFt#316 which were of the IgG2b isotype. 325 
Checkerboard competitive assays were performed by the indirect and direct cELISA 326 
formats. Regarding indirect assays, all antibodies recognized the homologous OVA 327 
conjugate, and most of them also afforded enough signal with one or more heterologous 328 
coating antigens (Table 2). IC50 values below 5 nM were obtained with most types of 329 
antibodies, except with those from haptens with the linker at a more central position of 330 
the molecule (TFa and TFc). Moreover, the mAbs recognized conjugates with the linker at 331 
equivalent positions, such as those of haptens TFe and TFo. Interestingly, no TFe- or TFo-332 
type antibody bound to conjugates of TFf or TFt, whereas several TFf- or TFt-type 333 
antibodies recognized OVA–TFe or OVA–TFo, or both of them. As a result, it could be 334 
stated that antibodies with the highest affinity were mainly obtained from haptens 335 
containing the spacer arm either at the methoxyacetate moiety (haptens TFe and TFo) or 336 
at the opposite side of the molecule (haptens TFb, TFf, and TFt). 337 
Concerning direct assays, the two TFb-type mAbs and most of the TFa-, TFc-, and 338 
TFt-type antibodies did not properly bind any enzyme tracer. Poor recognition of enzyme 339 
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tracers by mAbs directly immobilized to ELISA plates has been previously observed with 340 
other immunoreagents (Abad, Manclus, Mojarrad, Mercader, Miranda, Primo, et al., 1997; 341 
Butler, 2000; Manclus, Abad, Lebedev, Mojarrad, Mickova, Mercader, et al., 2004). 342 
Although the tracer recognition capacity of several anti-trifloxystrobin antibodies clearly 343 
improved when they were assayed in capture-antibody pre-coated plates (data not 344 
shown), this alternative assay format was not further explored with those mAbs. All of the 345 
TFe- and TFo-type antibodies afforded enough signal with both TFe and TFo tracers (Table 346 
3), and a similar behavior was observed between TFf- and TFt-type mAbs and tracers of 347 
TFt and TFf, respectively. Hapten heterology with this format afforded IC50 values to 348 
trifloxystrobin lower than the homologous assays with monoclonal TFf#13 combined with 349 
tracer HRP–TFc, and with mAb TFt#316 together with HRP–TFe. 350 
3.4. Antibody specificity to structural analogues  351 
The main structural motifs of the target analyte involved in antibody binding as a 352 
function of the immunizing hapten was studied by homologous indirect cELISA using as 353 
competitors a small collection of trifloxystrobin analogues carrying single structural 354 
differences that were designed to introduce steric and electronic modifications in the 355 
molecule (Table 1). Interestingly, high CR values were found (between 100% and 250%) 356 
with the iodinated analogue (TFa-I), independently of the antibody type. Equivalent or 357 
even superior recognition of iodinated analogues has been observed in our group with 358 
other strobilurins (unpublished results) and by other authors with brominated compounds 359 
(Sanvicens, Varela, & Marco, 2003; Suarez-Pantaleon, Mercader, Agullo, Abad-Somovilla, 360 
& Abad-Fuentes, 2011). Most probably, the increased hydrophobicity would compensate 361 
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the larger size of the molecule. On the other hand, analogues with slight modifications at a 362 
central position of the molecule, such as TFc-H and TFc-Et, showed varied CR values 363 
(between 10% and 100%) independently of the antibody origin, even though TFc-type 364 
antibodies, derived from the hapten with the linker at that position, coherently displayed 365 
the highest recognition of these two analogues (results not shown).  366 
Finally, when only the electron withdrawing trifluoromethyl group of 367 
trifloxystrobin was changed, remarkable results were found. As shown in Fig. 3, average 368 
CR values were near 100% for TFf- and TFt-type antibodies, independently of the 369 
modification that was introduced, as could be predicted by Landsteiner’s principle, i.e. 370 
antibody specificity is directed primarily to the portion of the hapten located furthest from 371 
or opposite to the functional group linking it to the carrier protein (Landsteiner, 1962). 372 
Besides, the analogue better mimicking the electron withdrawing properties of the 373 
trifluoromethyl group (TFf-NO2) was also well recognized by the other sorts of antibodies, 374 
particularly by TFb- and TFc-type mAbs – those generated from immunizing haptens with 375 
the spacer arm closer to the linker position of TFf. On the contrary, the presence of an 376 
electron donating group, such as -NH2 (TFf-NH2), drastically reduced the CR with TFa-, TFb-377 
, TFc-, TFe-, and TFo-type antibodies, which evidenced the relevance, for antibody binding, 378 
of the electronic modifications introduced by those moieties located opposite to the 379 
spacer arm of the immunizing hapten. Binding to an analogue with a neutral substituent 380 
(TFf-H) brought about an intermediate outcome. 381 
  382 
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4. Conclusions 383 
A battery of regioisomeric haptens was prepared with the same spacer arm – a C-6 384 
hydrocarbon chain ending in a carboxylate group – located at a variety of positions in 385 
order to cover the entire trifloxystrobin skeleton. In most cases, haptens were synthesized 386 
through formation of a C–C bond using Sonogashira cross-coupling methodology or 387 
C-alkylation reactions, whereas in other cases formation of a C–O bond using an 388 
O-alkylation reaction was followed. Carboxylate activation with DSC and purification of the 389 
active ester was shown to be an attractive strategy for immunogen and assay conjugate 390 
preparation by a single efficient procedure. A key influence of linker positioning over 391 
antibody affinity and specificity was revealed. For this agrochemical, derivatization over 392 
the methoxyacetate group – an aliphatic peripheral moiety with high-conformational 393 
freedom and displaying the aromatic and more rigid parts of the molecule – was shown to 394 
be the most adequate approach in terms of both synthetic convenience and antibody 395 
production. Several mAb/conjugate combinations were shown to be good candidates for 396 
immunoassay development with suitable analytical properties. 397 
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Fig. 1. A) Global minimum energy conformation of trifloxystrobin. Calculations were 
performed using Molecular Mechanics (MM3) as implemented in the CAChe program. 
A systematic conformational search was performed (all rotatable bonds were rotated 
by 15 degree steps) and the geometry of the generated conformers was refined by 
performing an optimize geometry calculation in MOPAC using PM3 parameters. This 
conformer represents the 2.6% of the equilibrium conformer population. Arrows 
denote the spacer-arm attachment site in each of the haptens. B) Structure of 
trifloxystrobin (TF), the synthesized haptens, and the corresponding N-succinimidyl 
esters (activated haptens). 
Fig. 2. Schematic diagram showing the rational design and general strategy followed 
for hapten synthesis. 
Fig. 3. Average CR values for three trifloxystrobin analogues obtained with the 






Analogue R1 R2 R3 
TFa-I CF3 CH3 I 
TFc-H CF3 H H 
TFc-Et CF3 C2H5 H 
TFf-NO2 NO2 CH3 H 
TFf-H H CH3 H 












IC50 values (nM) from checkerboard assays using the indirect 
cELISA format.a 
 OVA–hapten coating conjugateb 
mAb TFa TFb TFc TFe TFo TFf TFt 
TFa#11 20.5 –c – – – – – 
TFa#24 11.7 – – 12.2 – – – 
TFa#26 29.9 – – – 25.1 – – 
TFb#14 – 3.2 – 3.0 2.1 2.3 3.4 
TFb#32 – 16.7 20.7 – – 15.4 – 
TFc#146 – – 8.2 – – – – 
TFc#151 – – 17.4 – – – – 
TFc#163 – – 10.2 10.1 3.1 – – 
TFe#23 – – – 6.1 6.7 – – 
TFe#25 – – – 4.2 4.1 – – 
TFe#38 – – – 1.8 1.8 – – 
TFe#310 – – – 22.6 23.1 – – 
TFo#14 3.8 – – 8.5 5.5 – – 
TFo#110 12.1 – – 9.3 11.6 – – 
TFo#112 – – – – 8.0 – – 
TFf#13 – 3.5 2.7 2.4 – 2.9 5.1 
TFt#21 – – – – 4.0 5.1 4.4 
TFt#35 – – – – – 15.1 15.2 
TFt#211 1.4 1.8 – 2.4 – 3.8 5.3 
TFt#316 – – – 4.5 1.6 3.4 3.3 
a Average of three independent experiments. b Conjugate concentration was 
1.0 g mL−1. c No or low signal at the highest assayed antibody concentration 





IC50 values (nM) from checkerboard competitive assay using 
the direct cELISA format.a 
 HRP–hapten tracer conjugate 
mAbb TFa TFb TFc TFe TFo TFf TFt 
TFa#24 45.1 –c – – – – – 
TFc#163 – – 7.9 15.9 39.9 – – 
TFe#23 – – – 6.6 5.0 – – 
TFe#25 – – – 6.5 5.7 – – 
TFe#38 – – – 4.5 4.8 – – 
TFe#310 – – – 21.9 – – – 
TFo#14 – – – 6.5 8.5 – – 
TFo#110 – – – 7.5 7.3 – – 
TFo#112 – – – 6.2 7.3 – – 
TFf#13 – – 4.6 – – 8.1 5.6 
TFt#211 – – – 4.1 – 5.3 4.3 
TFt#316 – – – 5.2 – 10.5 9.7 
a Only those mAbs that recognized at least one enzyme tracer are shown. 
Values are the mean of three independent experiments. b Coating antibody 
concentration was 1.0 g mL−1. c No or low signal at the highest assayed 
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1. Synthesis of haptens 
1.1. General experimental details 
Infrared (IR) spectra were measured as KBr pellets for solid compounds or as thin films between NaCl 
plates for liquids, using a Nicolet Avatar 320 spectrometer; peaks are reported using the following 
abbreviations: s (strong), m (medium), w (weak). Melting points were determined using a Kofler hot-stage 
apparatus or a Büchi melting point apparatus and are uncorrected. NMR spectra were recorded at 25 °C on 
a Bruker AC-300 spectrometer (300.13 MHz for 1H and 75.47 MHz for 13C), and data are relative to Me4Si 
and referenced to residual solvent. Carbon substitution degrees were established by DEPT pulse 
sequences, and a combination of COSY and HSQC experiments was utilized for the assignment of 1H and 
13C chemical shifts. Spectral splitting patterns are designated as s (singlet), d (doublet), t (triplet), q 
(quadruplet), quint (quintuplet), m (multiplet), and br (broad). Mass spectra (MS) and high-resolution mass 
spectra (HRMS) were recorded with a Micromass VG Autospec spectrometer using for ionization electron 
impact (70 eV) or fast atom bombardment (FAB) or by the electrospray ionization (ESI) mode, which was 
obtained with a Q-TOF premier mass spectrometer with an electrospray source. 
Chemical reagents were purchased from regular sources and used without purification. All operations 
involving air-sensitive reagents were performed under an inert atmosphere of dry nitrogen or argon using 
syringe and cannula techniques, oven-dried glassware, and freshly distilled and dried solvents. Organic 
solvents were dried and distilled before use according to standard procedures.1 
Reactions were followed by thin-layer chromatography using 0.25 mm pre-coated silica gel plates and 
products were visualized by UV light (254 nm) and aqueous ceric ammonium molybdate solution or 50% 
(v/v) concentrated H2SO4 in water and then heating with a high-temperature air dryer. Unless otherwise 
stated, reaction mixtures were worked up by addition of water, and extraction with the appropriate solvent, 
the organic layer being washed with water and/or brine and dried using anhydrous magnesium or sodium 
sulfate. Evaporation of the solvent was performed under reduced pressure using a rotary evaporator. 
Synthesized compounds were purified by flash chromatography with a silica gel column (Merck 60, 230–
400 mesh).  
tert-Butyl hex-5-ynoate, tert-butyl 5-bromopentanoate and tert-butyl 6-bromohexanoate were prepared 
by esterification of commercial hex-5-ynoic acid, 5-bromopentanoic acid and 6-bromohexanoic acid, 





1.2. Synthesis of hapten TFa 
 
Figure S1. Synthetic sequence for the preparation of hapten TFa. 
Methyl 2-(4-iodo-2-methylphenyl)-2-oxoacetate (2). Methyl 2-chloro-2-oxoacetate (323 L, 3.510 mmol) 
was added to a solution of 3-iodotoluene (300 L, 511.2 mg, 2.340 mmol) in anhydrous CH2Cl2 (5 mL). The 
mixture was stirred for 10 min and then cooled to −30ºC followed by the addition of AlCl3 (1.2 g, 9.015 
mmol) in small portions (in about 10 min). The mixture was stirred at the same temperature for 90 min, 
during which the color changes to dark red. The reaction mixture was poured into a mixture of crushed ice 
and conc. HCl and extruded with CH2Cl2. The combined organics layers were washed successively with a 
10% aqueous solution of Na2S2O3, a 0.1 M solution of NaOH and brine, dried over anhydrous Na2SO4 and 
concentrated to give a residue that was purified by chromatography, using hexane–Et2O (9:1) as eluent, to 
afford, in order of elution, title compound 2 (348,6 mg, 49%), as a white solid, followed by methyl 2-oxo-2-
(m-tolyl)acetate (92.4 mg, 13%), as a colorless oil, and regioisomeric methyl 2-(2-iodo-4-methylphenyl)-2-
oxoacetate (248.5 mg, 35%) as a yellowish oil.  
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Physical and spectroscopic data of 2: Mp 8688 ºC (crystallized from hexane); IR (NaCl) max (cm−1) 
2954w, 2925w, 1734m, 1680s, 1585m, 1547m, 1429m, 1320m, 1203s, 922s, 912m, 735m; 1H-NMR (300 
MHz)  (ppm) 7.22 (1H, br s, H-3), 7.68 (1H, dd, J = 8.2, 1.5 Hz, H-5), 7.38 (1H, d, J = 8.2 Hz, H-6), 3.95 
(3H, s, CO2CH3), 2.53 (3H, s, CH3); 13C-NMR (75 MHz)  (ppm) 187.65 (CO), 164.22 (CO2CH3), 142.78 (C-
2), 141.30 (C-3), 135.21 (C-5), 133.04 (C-6), 130.67 (C-1), 102.23 (C-4), 52.90 (CO2CH3), 20.95 (CH3); MS 
(EI) m/z (%) 304 (M+, 7), 246 (9), 245 (100), 217 (12), 118 (5), 90 (17), 63 (5); HRMS m/z calcd. for 
C10H9IO3 303.9596, found 303.9595. 
(E)-Methyl 2-(4-iodo-2-methylphenyl)-2-(methoxyimino)acetate (3). A suspension of keto-ester 2 
(202.4 mg, 0.666 mmol) and N-methylhydroxylamine hydrochloride (240 mg, 2.87 mmol) in anhydrous 
pyridine (3.5 mL) was stirred at room temperature under nitrogen overnight. Work up as usual followed by 
purification by column chromatography with hexane–Et2O (from 8:2 to 6:4) as eluent afforded methoxyimino 
derivative 3 (157.2 mg, 71%) as a white solid. Mp 5052 ºC (crystallized from hexane); IR (KBr) max (cm−1) 
2940w, 2886w, 1725s, 1597w, 1437m, 1323m, 1219s, 1066s, 1018s, 957m, 846m, 780m; 1H-NMR (300 
MHz)  (ppm) 7.63 (1H, br s, H-3), 7.57 (1H, dd, J = 8.1, 1.4 Hz, H-5), 6.83 (1H, d, J = 8.1 Hz, H-6), 4.05 
(3H, s, NOCH3) 3.87 (3H, s, CO2CH3), 2.13 (3H, s, CH3); 13C-NMR (75 MHz)  (ppm) 163.07 (CO2CH3), 
149.69 (C=N), 138.83 (C-3), 138.33 (C-2), 134.61 (C-5), 129.64 (C-1), 129.50 (C-6), 95.64 (C-4), 63.85 
(NOCH3), 53.02 (CO2CH3), 19.14 (CH3); MS (EI) m/z (%) 333 (M+, 28), 302 (100), 270 (15), 259 (5), 243 
(59), 242 (30), 175 (8), 143 (8), 116 (20), 89 (15), 63 (5), 59 (8); HRMS m/z calcd. for C11H12INO3 332.9862, 
found 332.9867. 
(E)-Methyl 2-(2-(bromomethyl)-4-iodophenyl)-2-(methoxyimino)acetate (4). A mixture of 3 (300 mg, 
0.900 mmol), N-bromosuccinimide (NBS, 160 mg, 0.900 mmol), and azo-bis-isobutyronitrile (AIBN, 8.8 mg, 
0.054 mmol) in dry benzene (4 mL) was degassed by nitrogen bubbling and ultrasound for 15 min. The 
reaction mixture was refluxed under nitrogen for 14 h and the solvent was removed in the rotary evaporator 
to leave an oil that was purified by chromatography, using hexane–Et2O (9:1) as eluent, to give benzyl 
bromide 4 (248.4 mg, 67%) as a yellowish oil. IR (NaCl) max (cm−1) 3053w, 2941w, 1726s, 1595w, 1437m, 
1388d, 1325m, 1302m, 1266m, 1223s, 1063s, 1017s, 957m, 785m, 736s; 1H-NMR (300 MHz)  (ppm) 7.84 
(1H, d, J = 1.7 Hz, H-3), 7.70 (1H, dd, J = 8.1, 1.7 Hz, H-5), 6.88 (1H, d, J = 8.1 Hz, H-6), 4.23 (2H, s, 
CH2Br), 4.07 (3H, s, NOCH3), 3.88 (3H, s, CO2CH3); 13C-NMR (75 MHz)  (ppm) 162.71 (CO2CH3), 148.09 
(C=N), 138.97 (C-3), 137.71 (C-2), 137.45 (C-5), 130.21 (C-6), 129.79 (C-1), 95.64 (C-4), 64.02 (NOCH3), 
53.20 (CO2CH3), 29.37 (CH2Br); MS (EI) m/z (%) 414 (M++1 for 81Br, 12), 413 (M+ for 81Br, 97), 412 (M+ +1 
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for 79Br, 13), 411 (M+ for 79Br, 99), 380 (21), 378 (5), 332 (29), 301 (100), 272 (30), 269 (22), 258 (6), 242 
(36), 193 (2), 145 (13), 114 (10); HRMS m/z calcd. for C11H1179BrINO3 410.8967, found 410.8966. 
(E)-methyl 2-(4-iodo-2-((((E)-(1-(3-(trifluoromethyl)phenyl)ethylidene)amino)oxy)methyl) phenyl)-2-
(methoxyimino)acetate (6). A mixture of benzyl bromide 4 (105 mg, 0.255 mmol), oxime 5 (synthesized in 
the laboratory following the procedure described by Neufeldt et al.,3 55.3 mg, 0.255 mmol), and anhydrous 
Cs2CO3 (125 mg, 0.383 mmol) in dry DMF (1.2 mL) was stirred under nitrogen for 6 h, poured into water 
and worked up as usual using EtOAc to extract. Chromatography of the residue left after evaporation of the 
solvent, using hexane–Et2O (8:2) as eluent, afforded the benzyl ether 6 (128 mg, 92%) as a white solid. 
Mp.103–104 ºC (crystallized from hexane); IR (KBr) max (cm−1) 2946w, 2878w, 1725s, 1595w, 1369m, 
1340s, 1299m, 1277s, 1217m, 1169s, 1119s, 1068s, 1020s, 925m, 914m, 677m; 1H-NMR (300 MHz)  
(ppm) 7.86 (2H, br s, H-3 and H-2’), 7.78 (1H, d, J = 7.8 Hz, H-6’), 7.71 (1H, dd, J = 8.1, 1.7 Hz, H-5), 7.60 
(1H, d, J = 7.8 Hz, H-4’), 7.47 (1H, br t, J = 7.8 Hz, H-5’), 6.92 (1H, d, J = 8.1 Hz, H-6), 5.06 (2H, s, OCH2), 
4.03 (3H, s, NOCH3), 3.82 (3H, s, CO2CH3), 2.23 (3H, s, CH3); 13C-NMR (75 MHz)  (ppm) 162.90 
(CO2CH3), 154.10 (CH3CN), 148.70 (C=N), 138.23 (C-2), 137.67 (C-3), 137.00 (C-1’), 136.81 (C-5), 130.79 
(C-3’’, q, J = 32.5 Hz), 130.19 (C-6), 129.29 (C-6’), 129.20 (C-1),128.85 (C-5’), 125.72 (C-4’, q, J = 3.8 
Hz), 123.94 (CF3, q, J = 272.9 Hz), 122.88 (C-2’, q, J = 3.8 Hz), 95.62 (C-4), 73.99 (OCH2), 63.90 (NOCH3), 
52.97 (CO2CH3), 12.61 (CH3); MS (EI) m/z (%) 534 (M+, 0.1), 503 (12), 348 (100), 332 (50), 316 (33), 288 
(8), 272 (11), 256 (53), 243 (21), 242 (90), 198 (5), 186 (18), 146 (5); HRMS m/z calcd. for C20H18F3IN2O4 
534.0263, found 534.0282. 
tert-Butyl 6-(4-((E)-2-methoxy-1-(methoxyimino)-2-oxoethyl)-3-((((E)-(1-(3-(trifluoromethyl)phenyl) 
ethylidene)amino)oxy)methyl)phenyl)hex-5-ynoate (7). A solution of tert-butyl hex-5-ynoate (156 mg, 0.952 
mmol) in anhydrous degassed DMF (1.0 mL) was added to a mixture of aryl iodide 6 (127 mg, 0.238 mmol), 
CuI (1.3 mg, 0.007 mmol, 3% mol) and (Ph3P)2PdCl2 (5.0 mg, 0.007 mmol, 3% mol) under nitrogen 
atmosphere. After the addition anhydrous Et3N (0.5 mL) the reaction mixture, initially yellow that turned 
deep-orange after a few minutes, was stirred at room temperature for 6 h, then poured into water and 
worked up in the usual manner. Chromatography of the crude product with hexane–Et2O (7:3) as eluent 
afforded alkyne 7 (112.3 mg, 82%) as an oil. IR (NaCl) max (cm−1) 2977m, 2940s, 2231w, 1727s, 1609m, 
1493m, 1437s, 1368s, 1301s, 1275s, 1214s, 1127s, 1070s, 1017s, 951m, 899m, 834m, 788m, 698m; 1H-
NMR (300 MHz)  (ppm) 7.86 (1H, br s, H-2’’), 7.78 (1H, d, J = 7.7 Hz, H-6’’), 7.60 (1H, d, J = 7.8 Hz, H-
4’’), 7.51 (1H, d, J = 1.9 Hz, H-2’), 7.46 (1H, br t, J = 7.8 Hz, H-5’’), 7.39 (1H, dd, J = 7.9, 1.9 Hz, H-6’), 7.11 
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(1H, d, J = 7.9 Hz, H-5’), 5.09 (2H, s, OCH2), 4.02 (3H, s, NOCH3), 3.81 (3H, s, CO2CH3), 2.47 (2H, t, J = 
7.1 Hz, H2-4), 2.42 (2H, t, J = 7.4 Hz, H2-2), 2.22 (3H, s, CH3), 1.88 (2H, quint, J = 7.3 Hz, H2-3), 1.45 (9H, 
s C(CH3)3); 13C-NMR (75 MHz)  (ppm) 172.41 (CO2tBu), 163.05 (CO2CH3), 153.74 (CH3CN), 149.11 
(C=N), 137.11 (C-3’), 136.17 (C-1’’), 131.76 (C-2’), 130.72 (C-6’), 130.71 (C-3’’, q, J = 32.5 Hz), 129.17 (C-
6’’), 128.93 (C-4’), 128.77 (C-5’’), 128.57 (C-5’), 125.57 (C-4’’, q, J = 3.8 Hz), 125.09 (C-1’), 123.94 (CF3, q, 
J = 272.4 Hz), 122.83 (C-2’’, q, J = 3.8 Hz), 90.44 (C-5), 80.69 (C-6), 80.24 (C(CH3)3), 74.54 (OCH2), 63.73 
(NOCH3), 52.80 (CO2CH3), 34.32 (C-2), 28.05 (C(CH3)3), 24.00 (C-3), 18.80 (C-4),12.49 (CH3); MS (EI) m/z 
(%) 574 (M+, 14), 518 (72), 501 (33), 487 (4), 473 (4), 332 (12), 316 (12), 300 (9), 284 (10), 272 (23), 256 
(10), 242 (10), 226 (49), 212 (8), 199 (6), 187 (20), 186 (100); HRMS m/z calcd. for C30H33F3N2O6 574.2291, 
found 574.2284. 
tert-Butyl 6-(4-((E)-2-methoxy-1-(methoxyimino)-2-oxoethyl)-3-((((E)-(1-(3-(trifluoromethyl)phenyl) 
ethylidene)amino)oxy)methyl)phenyl)hexanoate (8). A mixture of alkyne 7 (117.8 mg, 0.205 mmol) and 
Rh(PPh3)3Cl (6 mg, 0.006 mmol) in anhydrous THF (1.9 mL) was stirred under an atmosphere of hydrogen 
at 4 atm overnight. The reaction mixture was concentrated to dryness and residue obtained purified by 
chromatography, using hexane–Et2O (8:2) as eluent, to give the title compound 8 (102 mg, 90%) as an oil. 
IR (NaCl) max (cm−1) 2975w, 2937m, 2858w, 1728s, 1613w, 1367m, 1341m, 1299m, 1275s, 1214m, 
1167s, 1127s, 1070s, 1021m; 1H-NMR (300 MHz)  (ppm) 7.87 (1H, br s, H-2’’), 7.79 (1H, d, J = 7.8 Hz, H-
6’’), 7.58 (1H, d, J = 7.8 Hz, H-4’’), 7.46 (1H, br t, J = 7.8 Hz, H-5’’), 7.29 (1H, d, J = 1.6 Hz, H-2’), 7.19 (1H, 
dd, J = 7.8, 1.6 Hz, H-6’), 7.11 (1H, d, J = 7.8 Hz, H-5’), 5.12 (2H, s, OCH2), 4.03 (3H, s, NOCH3), 3.81 (3H, 
s, CO2CH3), 2.65 (2H, t, J = 7.7, H2-6), 2.21 (5H, m, H2-2 and CH3), 1.72–1.57 (4H, m, H2-5 and H2-3), 
1.44–1.33 (11H, m, C(CH3)3 and H2-3); 13C-NMR (75 MHz)  (ppm) 173.12 (CO2tBu), 163.45 (CO2CH3), 
153.52 (CH3CN), 149.67 (C=N), 143.94 (C-1’), 137.26 (C-3’), 135.74 (C-1’’), 130.74 (C-3’’, q, J = 32.1 Hz), 
129.23 (C-6’’), 128.93 (C-2’), 128.78 (C-5’’), 128.54 (C-5’), 127.78 (C-6’), 127.13 (C-4’), 125.54 (C-4’’, q, J 
= 3.8 Hz), 124.00 (CF3, q, J = 272.5 Hz), 122.85 (C-2’’, q, J = 3.8 Hz), 79.95 (C(CH3)3), 75.14 (OCH2), 
63.68 (NOCH3), 52.80 (CO2CH3), 35.58 (C-6), 35.43 (C-2),30.67 (C-5), 28.79 (C-4), 28.08 (C(CH3)3), 24.90 
(C-3), 12.50 (CH3); MS (IE) m/z (%) 579 (M++1, 3), 505 (12), 376 (10), 336 (19), 320 (6), 288 (5), 276 (27), 
246 (6), 230 (31), 214 (10), 186 (40), 172 (11), 57 (100); HRMS m/z calcd. for C30H38F3N2O6 [M+H]+ 
579.2682, found 579.2690. 
6-(4-((E)-2-Methoxy-1-(methoxyimino)-2-oxoethyl)-3-((((E)-(1-(3-(trifluoromethyl)phenyl)ethylidene) 
amino)oxy)methyl)phenyl)hexanoic acid (hapten TFa). A solution of tert-butyl ester 8 (86 mg, 0.149 mmol) 
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in formic acid (3.3 mL) was stirred at room temperature under nitrogen for 3 h. Then the reaction mixture 
was diluted with benzene and washed with cold water until pH 6–7 and dried over anhydrous Na2SO4. 
Chromatographic purification of the residue left after evaporation of the solvent, using CHCl3–MeOH (99:1) 
as eluent, afforded hapten TFa (63.4 mg, 82%) as a colorless oil. IR (NaCl) max (cm−1) 3371m (broad), 
2984s, 2859m, 1738s, 1709s, 1614w, 1437m, 1341s, 1299s, 1275s, 1214s, 1167s, 1127s, 1070s, 1020s, 
737m, 699m; 1H-NMR (300 MHz)  (ppm) 7.87 (1H, br s, H-2’’), 7.78 (1H, d, J = 7.8 Hz, H-6’’), 7.59 (1H, br 
d, J = 7.8 HZ, H-4’’), 7.46 (1H, br t, J = 7.8 Hz, H-5’’), 7.29 (1H, br s, H-2’), 7.19 (1H, dd, J = 7.8, 1.6 Hz, H-
6’), 7.11 (1H, d, J = 7.8 Hz, H-5’), 5.12 (2H, s, OCH2), 4.03 (3H, s, NOCH3), 3.82 (3H, s, CO2CH3), 2.66 (2H, 
t, J = 7.5 Hz, H-6), 2.35 (2H, t, J = 7.4 Hz, H-2), 2.21 (3H, s, CH3), 1.71–1.56 (4H, m, H-3 and H-5), 1.42 
(2H, m, H-4); 13C-NMR (75 MHz)  (ppm) 178.40 (CO2H), 163.5 (CO2CH3), 153.6 (CH3C=N), 149.6 (C=N), 
143.8 (C-1’), 137.2 (C-3’), 135.8 (C-1’’), 130.8 (C-3’’, q, J = 32.5 Hz), 129.2 (C-6’’), 129(C-2’), 128.8 (C-5’’), 
128.6 (C-5’), 127.8 (C-6’), 127.2 (C-4’), 125.6 (C-4’’, q, J = 3.8 Hz), 124.0 (CF3, q, J = 272 Hz), 122.86 (C-
2’’, q, J = 3.8 Hz), 75.1 (OCH2), 63.7 (NOCH3), 52.8 (CO2CH3), 35.5 (C-6), 33.8 (C-2), 30.6 (C-5), 28.7 (C-
4), 24.5 (C-3), 12.5 (CH3); MS (EI) m/z (%) 522 (M+, 0.6), 491 (11), 337 (21), 336 (100), 320 (96), 304 (30), 
289 (5), 276 (45), 260 (12), 246 (37), 230 (45); HRMS m/z calcd for C26H29F3N2O6 522.1978, found 
522.1985; UV (100 mM sodium phosphate buffer, pH 7.4) Є (280 nm) 4.08 mM−1 cm−1. 
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1.3. Synthesis of hapten TFb 
 
Figure S2. Synthetic sequence for the preparation of hapten TFb.  
3-Bromo-5-(trifluoromethyl)benzoic acid (10). NBS (842 mg, 4.734 mmol) was added in small portions to 
a solution of 3-trifluoromethylbenzoic acid (600 mg, 3.156 mmol) in trifluoroacetic acid (1.6 mL) and conc. 
H2SO4 (480 L). The resulting suspension was vigorously stirred at room temperature overnight, poured 
into crushed ice-water and the solid which separated out was filtered and dried to give title compound 10 




3-Bromo-N-methoxy-N-methyl-5-(trifluoromethyl)benzamide (11). A solution of acid 10 (433.1 mg, 1.609 
mmol) in SOCl2 (1.7 mL, 2.785 g, 23 mmol) was refluxed under nitrogen for 4 h. The excess of SOCl2 was 
removed under vacuum and the residue dissolved in dry CH2Cl2 (5 mL). The obtained solution was added to 
a suspension of MeO(Me)NH·HCl (187 mg, 1.920 mmol) and Et3N (535 L (3.840 mmol) in anhydrous 
CH2Cl2 (10 mL) and the mixture stirred at room temperature under nitrogen for 18 h. After this time, the 
reaction mixture was poured into water and worked up in the usual way. Chromatography of the residue left 
after evaporation of the solvent, using hexane–EtOAc (from 9:1 to 8:2) as eluent, afforded amide 11 (488 
mg, 97%.) as a colorless oil. IR (NaCl) max (cm−1) 3076w, 2973w, 2939w, 1651s, 1578w, 1460m, 1414s, 
1384s, 1316s, 1207s, 1174s, 1132s, 1102s, 986m, 885m, 741m, 692s; 1H-NMR (300 MHz)  (ppm) 8.03 
(1H, br s, H-2), 7.91 (1H, br s, H-6), 7.85 (1H, br s, H-4), 3.55 (3H, s, OCH3), 3.38 (3H, s, CH3); 13C-NMR 
(75 MHz)  (ppm) 166.58 (CO), 136.42 (C-1), 134.71 (C-2), 132.14 (C-5, q, J = 32.6 Hz), 130.36 (C-4, q, J 
= 3.6 Hz), 124.03 (C-6, q, J = 3.6 Hz), 122.78 (CF3, q, J = 273.1 Hz), 122.36 (C-3), 61.39 (OCH3), 33.25 
(CH3); MS (EI) m/z (%) 314 (M++1 for 81Br, 10), 313 (M+ for 81Br, 95), 312 (M++1 for 79Br, 12), 311 (M+ for 
79Br, 98), 293 (2), 252 (94), 250 (100), 224 (23), 222 (23), 172 (3); HRMS m/z calcd. for C10H9F379BrNO2 
310.9769, found 310.9761. 
1-(3-Bromo-5-(trifluoromethyl)phenyl)ethanone (12). A 3 M solution of ClMgCH3 in THF (2.4 mL, 7.106 
mmol) was drop wise added to a solution of amide 11 (443.4 mg, 1.421 mmol) in dry THF (8.6 mL) under 
nitrogen at −78 ºC. The reaction mixture was allowed to warm to room temperature and stirred for 19 h, 
then cooled to 0 ºC, treated with a 1 M HCl and worked up as usually. Chromatographic purification, using 
hexaneEtOAc (8:2) as eluent, gave methyl ketone 12 (351.5 mg, 93%) as a colorless oil. IR (NaCl) max 
(cm−1) 3079w, 3006w, 1688s, 1604w, 1582w, 1361m, 1324s, 1239s, 1175s, 1134s, 1098m, 885m, 783m, 
692s; 1H-NMR (300 MHz)  (ppm) 8.25 (1H, br s, H-2), 8.11 (1H, br s, H-6), 7.95 (1H, br s, H-4), 2.64 (3H, 
s, CH3); 13C-NMR (75 MHz)  (ppm) 195.13 (CO), 139.05 (C-1), 134.58 (C-2), 132.87 (C-5, q, J = 32.8 Hz), 
132.53 (C-4, q, J = 3.8 Hz), 123.72 (C-6, q, J = 3.8 Hz), 123.38 (C-3), 122.70 (CF3, q, J = 272.9), 26.63 
(CH3); MS (EI) m/z (%) 268 (M+ for 81Br, 32), 266 (M+ for 79Br, 34), 253 (45), 250 (45), 225 (15), 144 (13), 97 
(23), 85 (50), 71 (65), 57 (100); HRMS m/z calcd. for C9H6F379BrO 265.9554, found 265.9542. 
tert-Butyl 6-(3-acetyl-5-(trifluoromethyl)phenyl)hex-5-ynoate (13). The synthesis of this compound was 
performed following the same procedure reported for compound 7, starting from aryl bromide 12 (330 mg, 
1.236 mmol), tert-butyl hex-5-ynoate (623 mg, 3.708 mmol), CuI (7.0 mg, 0.037 mmol), Pd(PPh3)2Cl2 (26 
mg, 0.037 mmol), DMF (5.3 mL), and Et3N (2.7 mL), and 2 h of reaction time. The crude product was 
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purified by chromatography, using hexane–Et2O (9:1) as eluent, to give alkyne 13 (371.9 mg, 85%) as an 
oil. IR (NaCl) max (cm−1) 2978w, 2928w, 1728m, 1698m, 1599w, 1449w, 1369m, 1352m, 1251s, 1172m, 
1134s; 1H-NMR (300 MHz)  (ppm) 8.11 (1H, br s, H-2’), 8.08 (1H, br s, H-4’), 7.82 (1H, br s, H-6’), 2.64 
(3H, s, CH3), 2.50 (2H, t, J = 7.2 Hz, H2-4), 2.41 (2H, t, J = 7.2 Hz, H2-2), 1.91 (2H, quint, J = 7.2 Hz, H2-3), 
1.46 (9H, s, C(CH3)3); 13C-NMR (75 MHz)  (ppm) 196.07 (CO), 172.32(CO2tBu), 137.55 (C-3’), 134.38 (C-
2’), 132.27 (C-6’, q, J = 3.6 Hz), 131.99 (C-5’, q, J = 32.6 Hz), 125.62 (C-1’), 123.77 (C-4’, q, J = 3.6 Hz), 
122.40 (CF3, q, J = 272.2), 92.45 (C-5), 80.49 (C-6), 79.09 (C(CH3)3), 34.37 (C-2), 28.10 (C(CH3)3), 26.68 
(CH3), 23.79 (C-3), 18.75 (C-4); MS (EI) m/z (%) 354 (M+, 0.2), 298 (23), 281 (16), 256 (10), 238 (21), 225 
(6), 205 (4), 182 (7), 57 (100); HRMS m/z calcd. for C19H21F3O3 354.1443, found 354.1436. 
tert-Butyl 6-(3-acetyl-5-(trifluoromethyl)phenyl)hexanoate (14). Alkyne 13 (166.1 mg, 0.469 mmol) was 
hydrogenated as described above for the preparation of 7 using Rh(PPh3)3Cl (13 mg, 0.003 mmol) and THF 
(4.3 mL). Purification of the crude product by chromatography with hexane–Et2O (9:1) as eluent gave title 
compound 14 (151.1 mg, 90%) as an oil. IR (NaCl) max (cm−1) 2978w, 2935w, 2863w, 1728m, 1694m, 
1606w, 1458w, 1368m, 1348m, 1245s, 1166s, 1129s; 1H-NMR (300 MHz)  (ppm) 8.00 (1H, br s, H-4’), 
7.94 (1H, br s, H-2’), 7.61 (1H, br s, H-6’), 2.73 (2H, t, J = 7.6 Hz, H2-6), 2.64 (3H, s, CH3), 2.21 (2H, t, J = 
7.3 Hz, H2-2), 1.73–1.56 (4H, m, H2-3 and H2-5), 1.42 (9H, s, C(CH3)3), 1.36 (2H, m, H2-3); 13C-NMR (75 
MHz)  (ppm) 196.93 (CO), 173.01 (CO2tBu), 144.33 (C-1’), 137.59 (C-3’), 131.32 (C-2’), 131.13 (C-5’, q, J 
= 32.5 Hz), 129.44 (C-6’, q, J = 3.5 Hz), 122.77 (C-4’, q, J = 3.5 Hz), 122.38 (CF3, q, J = 272.2), 80.07 
(C(CH3)3), 35.48 (C-6), 35.33 (C-2), 30.88 (C-5), 28.55 (C-3), 28.07 (C(CH3)3), 26.72 (CH3), 24.77 (C-4); 
MS (EI) m/z (%) 359 (M++1, 0.7), 303 (100), 285 (66), 200 (8), 165 (4), 153 (72), 137 (26), 134 (49); HRMS 
m/z calcd. for C19H25F3O3 358.1756, found 358.1742. 
(E)-tert-Butyl 6-(3-(1-(hydroxyimino)ethyl)-5-(trifluoromethyl)phenyl)hexanoate (15). Prepared as 
described above for the preparation of 3, starting from methyl ketone 14 (130.7 mg, 0.365 mmol), 
hydroxylamine chlorhydrate (101 mg, 1.460 mmol), and pyridine (2.5 mL). Chromatography of the crude 
product, using hexane–Et2O (8:2) as eluent, afforded oxime 15 (122.5 mg, 90%) as a colorless oil. IR 
(NaCl) max (cm−1) 3359 (broad), 2979w, 2934w, 2862w, 1728m, 1696m, 1604w, 1368m, 1319d, 1272s, 
1165s, 1126s, 1008w, 882w, 836w, 703w; 1H-NMR (300 MHz)  (ppm) 7.77 (1H, br s, OH), 7.69 (1H, br s, 
H-4’), 7.62 (1H, br s, H-2’), 7.42 (1H, br s, H-6’), 2.68 (2H, t, J = 7.6 Hz, H2-6), 2.29 (3H, s, CH3), 2.21 (2H, 
t, J = 7.3 Hz, H2-2), 1.72–1.55 (4H, m, H2-3 and H2-5), 1.43 (9H, s, C(CH3)3), 1.36 (2H, m, H2-3); 13C-NMR 
(75 MHz)  (ppm) 173.12 (CO2tBu), 155.12 (C=N), 143.76 (C-1’), 137.28 (C-3’), 130.95 (C-5’, q, J = 32.5 
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Hz), 129.18 (C-2’), 125.68 (C-6’, q, J = 3.8 Hz), 122.38 (CF3, q, J = 272.2), 120.42 (C-4’, q, J = 3.8 Hz), 
80.08 (C(CH3)3), 35.59 (C-6), 35.39 (C-2), 30.92 (C-5), 28.60 ( C-3), 28.07 (C(CH3)3), 24.83 (C-4), 11.95 
(CH3); MS (EI) m/z (%) 373 (M+, 0.6), 342 (1), 317 (37), 300 (44), 272 (4), 256 (4), 240 (4), 230 (23), 212 
(12), 198 (2), 184 (3), 158 (4), 146 (2), 57 (100); HRMS m/z calcd. for C19H26F3NO3 373.1865, found 
373.1857. 
tert-Butyl 6-(3-((E)-1-(((2-((E)-2-methoxy-1-(methoxyimino)-2-oxoethyl)benzyl)oxy)imino)ethyl)-5-
(trifluoromethyl)phenyl)hexanoate (17). This compound was prepared following the same procedure as for 
compound 6 starting from oxime 15 (58.3 mg, 0.156 mmol), benzyl bromide 16 (synthesized in the 
laboratory following a modification of literature procedures)5,6, 44.7 mg, 0.156 mmol), and Cs2CO3 (76.4 mg, 
0.234 mmol) in DMF (660 L). The crude product was purified by chromatography, using hexane–Et2O 
(from 9:1 to 8.5:1.5) as eluent, to give title compound 17 (78.7 mg, 87%) as a colorless oil. IR (NaCl) max 
(cm−1) 2984w, 2938w, 2848w, 1728s, 1598w, 1367m, 1279s, 1218m, 1164s, 1126s, 1069m, 1021m; 
1H-NMR (300 MHz)  (ppm) 7.76 (1H, br s, H-4’), 7.57 (1H, br s, H-2’), 7.49 (1H, dd, J = 7.4, 1.4 Hz, H-3’’), 
7.46–7.34 (3H, m, H-5’’, H-6’ and H-4’’), 7.18 (1H, dd, J = 7.4, 1.3 Hz, H-6’’), 5.13 (2H, s, OCH2), 4.03 (3H, 
s, NOCH3), 3.82 (3H, s, CO2CH3), 2.66 (2H, t, J = 7.7, H2-6), 2.25–2.17 (5H, m, H2-2 and CH3), 1.68–1.55 
(4H, m, H2-5 and H2-3), 1.42 (9H, s, C(CH3)3), 1.35 (2H, m, H2-3); 13C-NMR (75 MHz)  (ppm) 173.05 
(CO2tBu), 163.27 (CO2CH3), 153.90 (CH3CN), 149.50 (C=N), 143.61 (C-1’), 137.15 (C-1’’), 135.90 (C-3’), 
130.67 (C-5’, q, J = 31.9 Hz), 129.75 (C-2’’), 129.37 (C-4’’), 129.24 (C-2’), 128.72 (C-3’’), 128.48 (C-6’’), 
127.72 (C-5’’), 125.49 (C-6’, q, J = 3.7 Hz), 124.03 (CF3, q, J = 272.3 Hz), 120.43 (C-4’, q, J = 3.7 Hz), 
80.01 (C(CH3)3), 74.82 (OCH2), 63.77 (NOCH3), 52.87 (CO2CH3), 35.56 (C-6), 35.36 (C-2), 30.91 (C-5), 
28.61 (C-4), 28.04 (C(CH3)3), 24.81 (C-3), 12.66 (CH3); MS (EI) m/z (%) 505 (12), 342 (4), 300 (8), 222 
(47), 206 (60), 146 (14), 132 (56), 116 (100); FAB-HRMS m/z calcd. for C30H38F3N2O6 [M+H]+ 579.2637, 
found 579.2643. 
6-(3-((E)-1-(((2-((E)-2-Methoxy-1-(methoxyimino)-2-oxoethyl)benzyl)oxy)imino)ethyl)-5-(trifluoromethyl) 
phenyl)hexanoic acid (hapten TFb). Hydrolysis of the tert-butyl ester of 17 (78.7 mg, 0.136 mmol) with 
formic acid (2.8 mL) under the same conditions reported above for 8 afforded hapten TFb (65.9 mg, 93%) 
as a colorless oil. IR (NaCl) max (cm−1) 3314 (broad), 2939m, 2859w, 1726s, 1598w, 1279s, 1218m, 
1166m, 1124s, 1070m, 1020m, 956w, 886w, 703w; 1H-NMR (300 MHz)  (ppm) 7.66 (1H, br s, H-4’), 7.59 
(1H, br s, H-2’), 7.50 (1H, dd, J = 7.6, 1.5 Hz, H-3’’), 7.47–7.35 (3H, m, H-5’’, H-6’ and H-4’’), 7.19 (1H, dd, J 
= 7.4, 1.5 Hz, H-6’’), 5.14 (2H, s, OCH2), 4.03 (3H, s, NOCH3), 3.82 (3H, s, CO2CH3), 2.68 (2H, t, J = 7.5 
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Hz, H-6), 2.36 (2H, t, J = 7.3 Hz, H-2) 2.21 (3H, s, CH3), 1.72–1.62 (4H, m, H-3 and H-5), 1.40 (2H, m, H-4); 
13C-NMR (75 MHz)  (ppm) 179.2 (CO2H), 163.3 (CO2CH3), 153.9 (CH3C=N), 149.5 (C=N), 143.5 (C-1’), 
137.2 (C-1’’), 135.9 (C-3’), 130.7 (C-5’, q, J = 32 Hz), 129.6 (C-2’’), 129.4 (C-4’’), 129.3 (C-2’), 128.7 (C-3’’), 
128.5 (C-6’’), 127.7 (C-5’’), 125.6 (C-6’, q, J = 3.8 Hz), 124.0 (CF3, q, J = 273 Hz), 120.5 (C-4’, q, J = 3.8 
Hz), 74.9 (OCH2), 63.8 (NOCH3), 52.9 (CO2CH3), 35.5 (C-6), 33.7 (C-2), 30.8 (C-5), 28.5 (C-4), 24.4 (C-3), 
12.7 (CH3); EM (EI) m/z (%) 522 (M+, 0.5), 505 (1), 491 (5), 300 (32), 280 (6), 222 (96), 214 (13), 207 (12), 
206 (100), 190 (17), 116 (68); HRMS m/z calcd for C26H29F3N2O6 522.1978, found 522.1976; UV (100 mM 
sodium phosphate buffer, pH 7.4) Є (280 nm) 1.82 mM−1 cm−1. 
1.4. Synthesis of hapten TFc 
 
Figure S3. Synthetic sequence for the preparation of hapten TFc. 
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Allyl 3-oxo-3-(3-(trifluoromethyl)phenyl)propanoate (19). Methyl ketone 18 (1 g, 5.310 mmol) was drop 
wise added to a suspension of NaH (60 % dispersion in mineral oil, 532 mg, 13.27 mmol, prewashed with 
pentane) and diallyl carbonate (1.5 mL, 7.965 mmol) in dry benzene (5 mL) under nitrogen. The reaction 
mixture was heated at reflux for 5 h, and then cooled to 0 ºC, cautiously treated with 3 M aqueous HCl 
solution (20 mL) and extracted with CH2Cl2. Work up in the usual way and purification by chromatography, 
using hexane–EtOAc (9:1) as eluent, afforded the β-keto ester 19 (952.5 mg, 66%) as a yellowish oil. IR 
(NaCl) max (cm−1) 3038w, 2985w, 2943w, 1745s, 1696s, 1629m, 1440m, 1404m, 1328s, 1255s, 1170s, 
1129s, 1098m, 1074s, 990m, 932m, 802m, 694m; 1H-NMR (300 MHz)  (ppm) 8.20 (1H, br s, H-2’’), 8.13 
(1H, d, J = 7.8 Hz, H-6’’), 7.85 (1H, d, J = 7.8 Hz, H-4’’), 7.64 (1H, br t, J = 7.8 Hz, H-5’’), 5.88 (1H, m, H-
2’), 5.36–5.21 (2H, m, H2-3’), 4.66 (2H, dt, J = 5.7, 1.3 Hz, H2-1’), 4.05 (2H, s, H2-2); 13C-NMR (75 MHz) 
 (ppm) 191.05 (CO), 166.61 (COO), 136.42 (C-1’’), 131.65 (C-6’’), 131.32 (C-2’), 131.50 (C-3’’, q, J = 32.3 
Hz), 130.17 (C-4’’, q, J = 3.8 Hz), 129.53 (C-5’’), 125.35 (C-2’’, q, J = 3.8 Hz), 123.92 (CF3, q, J = 272.0 
Hz), 119.01 (C-3’), 66.26 (C-1’), 45.81 (C-2); MS (EI) m/z (%) 272 (M+, 4), 253 (2), 215 (8), 188 (35), 173 
(100), 159 (4), 145 (30); HRMS m/z calcd. for C13H11F3O3 272.0660, found 272.0668. 
1-Allyl 7-tert-butyl 2-(3-(trifluoromethyl)benzoyl)heptanedioate (20). A solution of β-keto ester 19 (400 
mg, 1.470 mmol) in dry DMF (2 mL) was drop wise added to a suspension of NaH (60% dispersion in 
mineral oil, 88 mg, 2.205 mmol, prewashed with pentane) in DMF (6 mL) at 0 ºC under nitrogen. After about 
30 min, when the evolution of hydrogen had ceased, tert-butyl 5-bromopentanoate (700 mg, 2.940 mmol) 
and KI (244 mg, 1.470 mmol) were added and the mixture was stirred at 50 ºC for 18 h. The reaction 
mixture was poured into water and worked up in the usual manner extracting with EtOAc. Chromatographic 
purification, using hexaneEt2O (from 8.5:1.5 to 8:2) as eluent, led to alkylated of β-keto ester 20 (463 mg, 
70%) as a yellow oil. IR (NaCl) max (cm−1) 2980m, 2933w, 2863w, 1729s, 1695m, 1611d, 1367m, 1331s, 
1254m, 1167s, 1127s, 1073m; 1H-NMR (300 MHz)  (ppm) 8.24 (1H, br s, H-2’’), 8.16 (1H, d, J = 7.8 Hz, 
H-6’’), 7.84 (1H, d, J = 7.8 Hz, H-4’’), 7.63 (1H, br t, J = 7.8 Hz, H-5’’), 5.87–5.72 (1H, m, H-2’), 5.27–5.12 
(2H, m, H2-3’), 4.58 (2H, br d, J = 5.8 Hz, H2-1’), 4.32 (1H, t, J = 7.2 Hz, H-2), 2.21 (2H, t, J = 7.4 Hz, H2-6), 
2.05 (2H, m, H2-4), 1.70–1.57 (4H, m, H2-3 and H2-5), 1.42 (9H, s, C(CH3)3); 13C-NMR (75 MHz)  (ppm) 
193.58 (CO), 172.74 (C-7), 169.08 (COO), 136.69 (C-1’’), 131.65 (C-6’’), 131.50 (C-3’’, q, J = 32.5 Hz), 
131.19 (C-2’), 129.88 (C-4’’, q, J = 3.7 Hz), 129.45 (C-5’’), 125.39 (C-2’’, q, J = 3.9 Hz), 123.50 (CF3, q, J = 
272.4 Hz), 118.96 (C-3’), 80.12 (C(CH3)3), 66.08 (C-1’), 54.01 (C-2), 35.10 (C-6), 28.43 (C-3), 28.03 
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(C(CH3)3), 26.88 (C-4), 24.75 (C-5); MS (EI) m/z (%)372 (4), 371 (5), 337 (7), 315 (4), 313 (7), 297 (8), 272 
(17), 182 (27), 173 (100); FAB-HRMS m/z calcd. for C22H28F3O5 [M+H]+ 429.1889, found 429.1984. 
tert-Butyl 7-oxo-7-(3-(trifluoromethyl)phenyl)heptanoate (21). A mixture of allyl ester 20 (214.3 mg, 0.500 
mmol), morpholine (87 L, 87.61 mg, 1.00 mmol), and Pd(PPh3)4 (32 mg, 0.027 mmol) in anhydrous THF 
(2.8 mL) was stirred at room temperature under nitrogen for 40 min. The reaction mixture was diluted with 
water and worked up as usually, extracting with EtOAc, and the crude product purified by chromatography, 
using hexane–Et2O (9:1) as eluent, to give title compound 21 (103.3 mg, 60%) as a colorless oil. IR (NaCl) 
max (cm−1) 3420m (broad), 2956w, 1739s, 1685s, 1601w, 1573w, 1457w, 1435w, 1317w, 1281w, 1179m, 
1129w, 1002m, 724m, 666m; 1H-NMR (300 MHz)  (ppm) 8.20 (1H, br s, H-2’), 8.12 (1H, d, J = 7.8 Hz, H-
6’), 7.80 (1H, d, J = 7.8 Hz, H-4’), 7.60 (1H, br t, J = 7.8 Hz, H-5’), 3.00 (2H, t, J = 7.2 Hz, H2-6), 2.24 (2H, t, 
J = 7.3 Hz, H2-2), 1.77 (2H, quint, J = 7.3 Hz, H2-3), 1.63 (2H, quint, J = 7.2 Hz, H2-5), 1.43 (9H, s, 
C(CH3)3), 1.41 (2H, m, H2-4); 13C-NMR (75 MHz)  (ppm) 198.70 (CO), 173.02 (COO), 137.44 (C-1’), 
131.18 (C-3’, q, J = 32.9 Hz), 131.13 (C-6’), 129.31 (C-4’, q, J = 3.6 Hz), 129.25 (C-5’), 124.82 (C-2’, q, J = 
3.8 Hz), 123.65 (CF3, q, J = 272.5 Hz), 80.06 (C(CH3)3), 38.39 (C-6), 35.31 (C-2), 28.61 (C-4), 28.07 
(C(CH3)3), 24.82 (C-5), 23.62 (C-3); MS (EI) m/z (%) 288 (25), 271 (18), 251 (23), 225 (20), 188 (94), 173 
(100), 145 (40); FAB-HRMS m/z calcd. for C18H23F3O3 344.1599, found 344.1598. 
(E)-tert-Butyl 7-(hydroxyimino)-7-(3-(trifluoromethyl)phenyl)heptanoate (22). Prepared as described 
above for the preparation of 3, starting from ketone 21 (98.4 mg, 0.286 mmol), hydroxylamine chlorhydrate 
(80 mg, 1.144 mmol), and pyridine (1.5 mL). Chromatography of the crude product, using hexane–Et2O 
(8:2) as eluent, afforded oxime 22 (99.4 mg, 97%) as a colorless oil. IR (NaCl) max (cm−1) 3365w (broad), 
2978w, 2933w, 2866w, 1728m, 1334m, 1269m, 1166s, 1127s, 1074m, 698m, 666m; 1H-NMR (300 MHz)  
(ppm) 7.95 (1H, br s, OH), 7.87 (1H, br s, H-2’), 7.77 (1H, d, J = 7.8 Hz, H-6’), 7.62 (1H, d, J = 7.8 Hz, 
H-4’), 7.50 (1H, br t, J = 7.8 Hz, H-5’), 2.82 (2H, t, J = 7.8 Hz, H2-6), 2.20 (2H, t, J = 7.4 Hz, H2-2), 1.65–
1.55 (4H, m, H2-5 and H2-3), 1.42 (9H, s, C(CH3)3), 1.40 (2H, m, H2-4); 13C-NMR (75 MHz)  (ppm) 173.14 
(CO2tBu), 158.58 (C=N), 136.52 (C-1’), 130.98 (C-3’, q, J = 32.3 Hz), 129.43 (C-6’), 129.05 (C-5’), 125.73 
(C-4’, q, J = 3.6 Hz), 124.45 (CF3, q, J = 272.4 Hz), 123.04 (C-2’, q, J = 3.9 Hz), 80.10 (C(CH3)3), 35.34 (C-
2), 29.04 (C-4), 28.06 (C(CH3)3), 25.89 (C-5), 25.63 (C-6), 24.71 (C-3); MS (EI) m/z (%) 359 (M+, 0.1), 303 
(5), 286 (14), 240 (1), 203 (20), 187 (2), 178 (4), 145 (5), 97 (2), 83 (2), 71 (2), 69 (8), 57 (100); HRMS m/z 




phenyl)heptanoate (23). This compound was prepared following basically the procedure already described 
for compound 6 starting from oxime 22 (32.8 mg, 0.091 mmol), benzyl bromide 16 (31.2 mg, 0.109 mmol), 
and Cs2CO3 (44 mg, 0.136 mmol) in DMF (1.0 mL) and 4 h of reaction time. The crude product was purified 
by chromatography, using hexane–Et2O (8:2) as eluent, to give title compound 23 (50.4 mg, 98%) as a 
colorless oil. IR (NaCl) max (cm−1) 2980w, 2939m, 2869w, 1728s, 1344m, 1304m, 1276m, 1218m, 1127s, 
1072s, 1019m; 1H-NMR (300 MHz)  (ppm) 7.88 (1H, br s, H-2’’), 7.75 (1H, d, J = 7.8 Hz, H-6’’), 7.59 (1H, 
d, J = 7.8 Hz, H-4’’), 7.49 (1H, m, H-3’ partially overlapped with H-5’, H-4’ and H-5’’), 7.46 (1H, m, H-5’’ 
partially overlapped with H-5’, H-4’ and H-3’) 7.40 (1H, m, H-4’ partially overlapped with H-5’, H-3’ and H-
5’’), 7.38 (1H, m, H-5’ partially overlapped with H-5’, H-6’ and H-5’’), 7.18 (1H, dd, J = 7.3, 1.2 Hz, H-6’), 
5.11 (2H, s, OCH2), 4.04 (3H, s, NOCH3), 3.81 (3H, s, CO2CH3), 2.74 (2H, t, J = 7.6 Hz, H2-6), 2.17 (2H, t, J 
= 7.6 Hz, H2-2), 1.50–1.40 (4H, m, H2-5 and H2-3), 1.42 (9H, s, C(CH3)3), 1.37 (2H, m, H2-4); 13C-NMR (75 
MHz)  (ppm) 172.99 (CO2tBu), 163.26 (CO2CH3), 157.49 (CH2CN), 149.35 (C=N), 136.39 (C-1’), 136.12 
(C-1’’), 130.81 (C-3’’, q, J = 32.3 Hz), 129.50 (C-4’), 129.48 (C-2’), 129.42 (C-6’’), 128.82 (C-3’), 128.54 
(C-5’’), 128.40 (C-6’), 127.61 (C-5’), 125.56 (C-4’’, q, J = 3.7 Hz), 123.96 (CF3, q, J = 272.3 Hz), 123.04 (C-
2’’, q, J = 3.9 Hz), 80.00 (C(CH3)3), 74.49 (OCH2), 63.79 (NOCH3), 52.89 (CO2CH3), 35.30 (C-2), 29.12 (C-
4), 28.06 (C(CH3)3), 26.21 (C-6), 26.06 (C-3), 24.71 (C-5); MS (EI) m/z (%) 564 (M+, 1), 509 (1), 508 (5), 
491 (8), 477 (1), 342 1), 317 (2), 286 (16), 240 (5), 222 45), 206 (100); HRMS m/z calcd. for C29H35F3N2O6 
564.2447, found 564.2437. 
(E)-7-(((2-((E)-2-Methoxy-1-(methoxyimino)-2-oxoethyl)benzyl)oxy)imino)-7-(3-(trifluoromethyl)phenyl) 
heptanoic acid (hapten TFc). Hydrolysis of the tert-butyl ester of 23 (58.8 mg, 0.104 mmol) with formic acid 
(2.1 mL) under the same conditions reported above for 8 afforded, after chromatographic purification with 
CHCl3 as eluent, hapten TFc (49.7 mg, 94%) as a colorless oil. IR (NaCl) max (cm−1) 3339 (broad), 2941s, 
2853m, 2689w, 1728s, 1711s, 1607w, 1437s, 1340s, 1304s, 1277s, 1220s, 1168s, 1127s, 1071s, 1019s, 
958m, 699m; 1H-NMR (300 MHz)  (ppm) 7.85 (1H, br s, H-2’’), 7.75 (1H, d, J = 7.8 Hz, H-6’’), 7.59 (1H, d, 
J = 7.8 Hz, H-4’’), 7.49-7.37 (4H, m, H-3’, H-4’, H-5’, and H-5’’), 7.19 (1H, dd, J = 7.7, 1.5 Hz, H-6’), 5.11 
(2H, s, OCH2), 4.04 (3H, s, NOCH3), 3.81 (3H, s, CO2CH3), 2.74 (2H, t, J = 7.9 Hz, H-6), 2.31 (2H, t, J = 7.4 
Hz, H-2), 1.63 (2H, quint, J = 7.5 Hz, H-3), 1.53 (2H, M, H-5), 1.39 (2H, m, H-4); 13C-NMR (75 MHz)  (ppm) 
179.1 (CO2H), 163.3 (CO2CH3), 157.4 (CH2C=N), 149.4 (C=N), 136.3 (C-1’), 136.1 (C-1’’), 130.9 (C-3’’, q, J 
= 32 Hz), 130.2 (C-2’), 129.5 (C-4’), 129.4 (C-6’’), 128.9 (C-3’), 128.6 (C-5’’), 128.4 (C-6’) 127.7 (C-5’), 
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125.6 (C-4’’, q, J = 3.8 Hz), 123.9 (CF3, q, J = 272Hz), 123.1 (C-2’’, q, J = 3.8 Hz), 74.5 (OCH2), 63.8 
(NOCH3), 52.9 (CO2CH3), 33.7 (C-2), 29.0 (C-4), 26.1 (C-6), 26.0 (C-5), 24.2 (C-3); MS (EI) m/z (%) 508 
(M+, 1), 491 (2), 286 (8), 266 (3), 222 (35), 206 (88), 190 (7), 187 (9), 172 (6), 116 (100); HRMS m/z calcd 
for C26H27F3N2O6 508.1821, found 508.1807; UV (100 mM sodium phosphate buffer, pH 7.4) Є (280 nm) 
3.36 mM−1 cm−1. 
1.5. Synthesis of hapten TFe. 
 
Figure S4. Synthetic sequence for the preparation of hapten TFe. 
(E)-2-(Methoxyimino)-2-(2-((((E)-(1-(3-(trifluoromethyl)phenyl)ethylidene)amino)oxy)methyl)phenyl)acetic 
acid (24). A solution of trifloxystrobin (5.0 g, 12.24 mmol) in a mixture of 5 M aqueous sodium hydroxide 
(12.5 mL) and methanol (70 mL) was stirred under reflux for 5 h. The methanol evaporated and the residue 
obtained diluted with water and extracted with EtOAc. The aqueous layer was acidified to pH 2–3 with 5 M 
aqueous HCl solution and extracted with EtOAc. Work up as usual and purification by crystallization from 
hexane–acetone afforded acid 24 (3.52 g, 73%) as a white solid. The physical and spectroscopic properties 
of this compound have been previously described.7,8  
tert-Butyl 6-((E)-2-(methoxyimino)-2-(2-((((E)-(1-(3-(trifluoromethyl)phenyl)ethylidene)amino)oxy)methyl) 
phenyl)acetoxy)hexanoate (25). A mixture of acid 24 (100 mg, 0.253 mmol), tert-butyl 6-bromohexanoate 
(76.2 mg, 0.304 mmol), and anhydrous K2CO3 (42 mg, 0.304 mmol) in dry DMF (10 mL) was stirred at room 
temperature for 24 h. The reaction mixture was poured into water and worked up in the usual manner 
extracting with EtOAc. Purification of the crude product by chromatography, using hexane–Et2O (from 9:1 to 
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7:3) as eluent, afforded title compound 25 as a colorless oil (100 mg, 70%). IR (NaCl) max (cm−1) 2984w, 
2940m, 2859w, 1725s, 1618w, 1459w, 1368m, 1341m, 1298m, 1275s, 1216m, 1167s, 1127s, 1071s, 
1014m; 1H-NMR (300 MHz)  (ppm) 7.86 (1H, br s, H-2’’), 7.79 (1H, d, J = 7.9 Hz, H-6’’), 7.59 (1H, d, J = 
7.9 Hz, H-4’’), 7.48 (1H, m, H-6’ partially overlapped with H-4’, H-5’ and H-5’’), 7.46 (1H, m, H-5’’ partially 
overlapped with H-4’, H-5’ and H-6’) 7.42 (1H, m, H-5’ partially overlapped with H-4’, H-6’ and H-5’’), 7.37 
(1H, m, H-4’ partially overlapped with H-5’, H-6’ and H-5’’), 7.18 (1H, dd, J = 7.5, 1.8 Hz, H-3’), 5.14 (2H, s, 
OCH2), 4.20 (2H, t, J = 6.8 Hz, H2-6), 4.02 (3H, s, NOCH3), 2.23 (3H, s, CH3), 2.15 (2H, t, J = 7.4 Hz, H2-2), 
1.65 (2H, quint, J= 7.3 Hz, H2-5), 1.54 (2H, quint, J = 7.3 Hz, H2-3), 1.43 (9H, s, C(CH3)3), 1.30 (2H, m, H2-
4); 13C-NMR (75 MHz)  (ppm) 172.86 (CO2tBu), 162.87 (CO2CH2), 151.90 (CH3CN), 149.68 (C=N), 137.18 
(C-2’), 135.90 (C-1’’), 129.80 (C-3’’, q, J = 32.1 Hz), 129.28 (C-5’ and C-6’’), 128.81 (C-6’), 128.61 (C-5’’), 
128.49 (C-3’), 127.68 (C-4’), 127.32 (C-1’), 125.62 (C-4’’, q, J = 3.8 Hz), 123.96 (CF3, q, J = 272.6 Hz), 
122.88 (C-2’’, q, J = 3.8 Hz), 80.07 (C(CH3)3), 74.89 (C-6), 65.77 (OCH2), 63.73 (NOCH3), 35.28 (C-2), 
28.16 (C-5), 28.08 (C(CH3)3), 25.23 (C-4), 24.37 (C-3), 12.57 (CH3); MS (EI) m/z (%) 564 (M+, 0.2), 533 (2), 
509 (1), 491 (8), 322 (35), 192 (79), 186 (42), 172 (5), 145 (12), 132 (8), 116 (94), 115 (43), 97 (19), 69 (32), 
57 (100); HRMS m/z calcd. for C29H35F3N2O 564.2447, found 564.2447. 
6-((E)-2-(Methoxyimino)-2-(2-((((E)-(1-(3-(trifluoromethyl)phenyl)ethylidene)amino)oxy)methyl)phenyl) 
acetoxy)hexanoic acid (hapten TFe). Hydrolysis of the tert-butyl ester of 25 (32.7 mg, 0.079 mmol) with 
formic acid (1.6 mL) under the same conditions reported above for 8 afforded, after chromatographic 
purification with CHCl3 as eluent, hapten TFe (30.3 mg, 93%) as a colorless oil. IR (NaCl) max (cm−1) 3347 
(broad), 3063w, 2941m, 1713s, 1608w, 1586w, 1341s, 1299s, 1276s, 1168s, 1126s, 1071s, 1014s, 738m, 
698m; 1H-NMR (300 MHz)  . (ppm) 7.86 (1H, br s, H-2’’), 7.79 (1H, d, J = 7.8 Hz, H-6’’), 7.59 (1H, d, J = 
7.8 Hz, H-4’’), 7.48 (1H, m, H-6’), 7.46 (1H, m, H-5’’), 7.42 (1H, m, H-5’), 7.37 (1H, m, H-4’), 7.18 (1H, dd, J 
= 7.6, 1.7 Hz, H-3’), 5.15 (2H, s, OCH2), 4.21 (2H, t, J = 6.7 Hz, H-6), 4.02 (3H, s, NOCH3), 2.31 (2H, t, J = 
7.3 Hz, H-2) 2.23 (3H, s, CH3), 1.72–1.52 (4H, m, H-3 and H-5), 1.31 (2H, m ,H-4); 13C-NMR (75 MHz)  
(ppm) 179.3 (CO2H), 162.8 (CO2CH2), 153.66 (CH3C=N), 149.65 (C=N), 137.1 (C-2’), 135.9 (C-1’’), 130.7 
(C-3’’, q, J = 32 Hz), 129.9 (C-1’), 129.3 (C-5’ and C-6’’), 128.8 (C-6’), 128.6 (C-5’’), 128.5 (C-3’), 127.7 (C-
4’), 125.6 (C-4’’, q, J = 3.8 Hz), 123.9 (CF3, q, J = 272 Hz), 122.8 (C-2’’, q, J = 3.8 Hz), 74.9 (C-6), 65.6 
(OCH2), 63.7 (NOCH3), 33.7 (C-2), 28.0 (C-5), 25.2 (C-4), 24.1 (C-3), 12.6 (CH3); MS (EI) m/z (%) 444 (2), 
286 (5%, 192 (36), 121 (21), 116 (100), 69 (46); FAB-HRMS m/z calcd for C25H28F3N2O6 [M+H]+ 509.1900, 
found 509.1901; UV (100 mM sodium phosphate buffer, pH 7.4) Є (280 nm) 2.80 mM−1 cm−1. 
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1.6. Synthesis of hapten TFo 
 
Figure S5. Synthetic sequence for the preparation of hapten TFo. 
(E)-tert-Butyl 6-(((2-methoxy-2-oxo-1-(o-tolyl)ethylidene)amino)oxy)hexanoate (27). A mixture of oxime 
26 (synthesized in the laboratory following the procedure described by Li et al.,9,10 90 mg, 0.466 mmol), tert-
butyl 6-bromohexanoate (117 mg, 0.466 mmol), and anhydrous Cs2CO3 (228 mg, 0.699 mmol) in dry DMF 
(1.7 mL) was stirred under nitrogen for 4 h, poured into water and worked up as usual using EtOAc to 
extract. Chromatography of the crude product, using hexane–EtOAc (9:1) as eluent, afforded the 
corresponding O-alkylated oxime 27 (141 mg, 83%) as a colorless oil. IR (NaCl) max (cm−1) 2973m, 2937m, 
2858m, 1728s, 1655w, 1367m, 1321m, 1279d, 1219m, 1152m, 1068m, 998m, 755m; 1H-NMR (300 MHz)  
(ppm) 7.30 (1H, td, J = 7.6, 7.0, 1.1 Hz, H-5’), 7.18 (2H, m, H-4’ and H-6’), 7.09 (1H, dd, J = 7.3, 1.7 Hz, H-
3’), 4.25 (2H, t, J = 6.8 Hz, H2-6), 3.86 (3H, s, CO2CH3), 2.18 (3H, s, CH3), 2.17 (2H, t, J = 7.4 Hz, H2-2), 
1.68 (2H, quint, J= 7.1 Hz, H2-5), 1.56 (2H, quint, J = 7.4 Hz, H2-3), 1.43 (9H, s, C(CH3)3), 1.29 (2H, m, H2-
4); 13C-NMR (75 MHz)  (ppm) 172.90 (CO2tBu), 163.72 (CO2CH3), 149.79 (C=N), 135.95 (C-2’), 130.60 
(C-1’), 129.86 (C-6’), 129.15 (C-5’), 127.91 (C-3’), 125.42 (C-4’), 80.01 (C(CH3)3), 76.05 (C-6), 52.86 
(CO2CH3), 35.38 (C-2), 28.74 (C-5), 28.09 (C(CH3)3), 25.16 (C-4), 24.74 (C-3), 19.53 (CH3); MS (EI) m/z 
(%) 363 (M+, 0.2), 308 (0.4), 276 (4), 234 (19), 233 (15), 218 (6), 176 (65), 132 (29), 118 (22), 117 (34), 57 
(100); HRMS m/z calcd. for C20H29NO5 363.2046, found 363.2044. 
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(E)-tert-Butyl 6-(((1-(2-(bromomethyl)phenyl)-2-methoxy-2-oxoethylidene)amino)oxy)hexanoate (28). A 
solution of O-alkyloxime 27 (123 mg, 0.339 mmol), NBS (60.3 mg, 0.339 mmol), and AIBN (3.3 mg, 0.020 
mmol) in anhydrous benzene (1.5 mL) was degassed by nitrogen bubbling and ultrasound for 15 min and 
then heated at reflux overnight. The reaction mixture was allowed to cool room temperature, diluted with 
EtOAc and worked up as usual to afford the crude product as a pale brown oil. Purification by column 
chromatography, using hexane–Et2O (from 9:1 to 8:2) as eluent, gave benzyl bromide 28 (137.8, 92%) as a 
brownish oil. IR (NaCl) max (cm−1) 2970w, 2938w, 1728s, 1588w, 1367m, 1219m, 1152s, 1066m, 1001m; 
1H-NMR (300 MHz)  (ppm) 7.48 (1H, dd, J = 7.4, 1.6 Hz, H-6’), 7.40 (1H, td, J = 7.4, 7.3, 1.7 Hz, H-5’) 
7.35 (1H, td, J = 7.3, 7.3, 1.6 Hz, H-4’), 7.13 (1H, dd, J = 7.3, 1.7 Hz, H-3’), 4.33 (2H, s, CH2Br), 4.27 (2H, t, 
J = 6.9 Hz, H2-6), 3.87 (3H, s, CO2CH3), 2.16 (2H, t, J = 7.3 Hz, H2-2), 1.68 (2H, quint, J = 7.1 Hz, H2-5), 
1.54 (2H, quint, J = 7.3 Hz, H2-3), 1.42 (9H, s, C(CH3)3), 1.28 (2H, m, H2-4); 13C-NMR (75 MHz)  (ppm) 
172.90 (CO2tBu), 163.77 (CO2CH3), 149.57 (C=N), 138.22 (C-2’), 130.58 (C-1’), 130.11 (C-6’), 129.72 
(C-5’), 128.67 (C-3’), 128.38 (C-4’), 80.04 (C(CH3)3), 76.34 (C-6), 53.07 (CO2CH3), 35.34 (C-2), 30.88 
(CH2Br), 28.69 (C-5), 28.08 (C(CH3)3), 25.13 (C-4), 24.70 (C-3); MS (EI) m/z (%) 384 (10), 354 (11), 307 
(33), 256 (32), 175 (55), 146 (60), 116 (100); FAB-HRMS m/z calcd. for C20H2979BrNO5 [M+H]+ 442.1229, 
found 442.1181. 
tert-Butyl 6-(((E)-(2-methoxy-2-oxo-1-(2-((((E)-(1-(3-(trifluoromethyl)phenyl)ethylidene)amino)oxy)methyl) 
phenyl)ethylidene)amino)oxy)hexanoate (29). This compound was prepared following the procedure 
described above for compound 6 starting from benzyl bromide 28 (52.2 mg, 0.118 mmol), oxime 5 (25.6 mg, 
0.118 mmol), and Cs2CO3 (57.6 mg, 0.177 mmol) in DMF (0.5 mL) and 6 h of reaction time. The crude 
product was purified by chromatography, using hexane–Et2O (from 9:1 to 8:2) as eluent, to give title 
compound 29 (62.6 mg, 92%) as a colorless oil. (NaCl) max (cm−1) 2974m, 2938m, 1723s, 1608d, 1590w, 
1437m, 1368m, 1341s, 1299m, 1275s, 1219m, 1167s, 1127s, 1072s, 1000m, 698m, 672m; 1H-NMR (300 
MHz)  (ppm) 7.86 (1H, br s, H-2’’), 7.79 (1H, d, J = 7.9 Hz, H-6’’), 7.59 (1H, d, J = 7.9 Hz, H-4’’), 7.48 (1H, 
m, H-6’ partially overlapped with H-4’, H-5’ and H-5’’), 7.46 (1H, m, H-5’’ partially overlapped with H-4’, H-
5’ and H-6’) 7.42 (1H, m, H-5’ partially overlapped with H-4’, H-6’ and H-5’’), 7.38 (1H, m, H-4’ partially 
overlapped with H-5’, H-6’ and H-5’’), 7.18 (1H, dd, J = 7.1, 1.7 Hz, H-3’), 5.14 (2H, s, OCH2), 4.23 (2H, t, J 
= 6.9 Hz, H2-6), 3.80 (3H, s, CO2CH3), 2.22 (3H, s, CH3), 2.11 (2H, t, J = 7.4 Hz, H2-2), 1.66 (2H, quint, J = 
7.2 Hz, H2-5), 1.54 (2H, quint, J = 7..4 Hz, H2-3), 1.42 (9H, s, C(CH3)3), 1.27 (2H, m, H2-4); 13C-NMR (75 
MHz)  (ppm) 172.89 (CO2tBu), 163.45 (CO2CH3), 153.54 (CH3CN), 149.24 (C=N), 137.17 (C-2’), 135.87 
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(C-1’’), 130.70 (C-3’’, q, J = 32.0 Hz), 129.99 (C-1’), 129.23 (C-6’’), 129.22 (C-5’), 128.79 (C-6’), 128.64 
(C-5’’), 128.49 (C-3’), 127.69 (C-4’), 125.56 (C-4’’, q, J = 3.8 Hz), 123.90 (CF3, q, J = 272.0 Hz), 122.82 (C-
2’’, q, J = 3.8 Hz), 79.99 (C(CH3)3), 76.13 (C-6), 74.91 (OCH2), 52.80 (CO2CH3), 35.32 (C-2), 28.68 (C-5), 
28.05 (C(CH3)3), 25.11 (C-4), 24.70 (C-3), 12.50 (CH3); MS (EI) m/z (%) 377 (4), 362 (4), 323 (12), 322 
(70), 319 (6), 307 (7), 306 (39), 304 (18), 192 (61), 186 (87), 172 (12), 160 (12), 148 (32), 132 (12), 116 
(100); FAB-HRMS m/z calcd. for C29H36F3N2O6 [M+H]+ 565.2525, found 565.2526. 
6-(((E)-(2-Methoxy-2-oxo-1-(2-((((E)-(1-(3-(trifluoromethyl)phenyl)ethylidene)amino)oxy)methyl)phenyl) 
ethylidene)amino)oxy)hexanoic acid (hapten TFo). Hydrolysis of the tert-butyl ester of 29 (88.8 mg, 0.154 
mmol) with formic acid (3.2 mL) under the same conditions reported above for 8 afforded, after 
chromatographic purification with CHCl3–MeOH (99:1) as eluent, hapten TFo (73.6 mg, 92%) as a colorless 
oil. IR (NaCl) max (cm−1) 3314 (broad), 2948m, 2880m, 1727s, 1709s, 1608w, 1586w, 1341s, 1275s, 
1167s, 1120s, 1072s, 1001s, 737m, 698m ; 1H-NMR (300 MHz)  (ppm) 7.86 (1H, br s, H-2’’), 7.79 (1H, d, J 
= 7.8 Hz, H-6’’), 7.59 (1H, d, J = 7.8 Hz, H-4’’), 7.48 (1H, m, H-6’), 7.46 (1H, m, H-5’’), 7.42 (1H, m, H-5’), 
7.37 (1H, m, H-4’), 7.17 (1H, dd, J = 7.4, 1.5 Hz, H-3’), 5.14 (2H, s, OCH2), 4.24 (2H, t, J = 6.7 Hz, H-6), 
3.81 (3H, s, CO2CH3), 2.29 (2H, t, J = 7.4 Hz, H-2), 2.22 (3H, s, CH3), 1.67 (2H, quint, J = 7.4 Hz, H-5), 1.59 
(2H, quint, J = 7.4Hz, H-3), 1.30 (2H, m, H-4); 13C-NMR (75 MHz)  (ppm) 179.4 (CO2H), 163.5 (CO2CH3), 
153.6 (CH3C=N), 149.3 (C=N), 137.1 (C-2’), 135.8 (C-1’’), 130.7 (C-3’’, q, J = 32 Hz), 129.9 (C-1’), 129.3 (C-
5’ and C-6’’), 128.8 (C-6’), 128.6 (C-5’’),128.5 (C-3’), 127.7 (C-4’), 125.59 (C-4’’, q, J = 3.8 Hz), 124.0 (CF3, 
q, J = 272 Hz), 122.8 (C-2’’, q, J = 3.8 Hz), 75.97 (C-6), 74.9 (OCH2), 52.8 (CO2CH3), 33.7 (C-2), 28.6 (C-5), 
25.1 (C-4), 24.2 (C-3), 12.5 (CH3); FAB-HRMS m/z calcd for C25H28F3N2O6 [M+H]+ 509.1899, found 
509.1912; UV (100 mM sodium phosphate buffer, pH 7.4) Є (280 nm) 3.47 mM−1 cm−1. 
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1.7. Synthesis of haptens TFf and TFt 
 
 
Figure S6. Synthetic sequence for the preparation of haptens TFf and TFt. 
tert-Butyl 6-(3-acetylphenyl)hex-5-ynoate (31). The synthesis of this compound was performed following 
the same procedure described above for compound 7, starting from 1-(3-bromophenyl)ethanone (30, 360.3 
mg, 1.810 mmol), tert-butyl hex-5-ynoate (912.7 mg, 4.430 mmol), CuI (10.3 mg, 0.054 mmol), 
Pd(PPh3)2Cl2 (38 mg, 0.044 mmol), DMF (5.5 mL), and Et3N (3.0 mL), and 6 h of reaction time. The crude 
product was purified by chromatography, using hexane–Et2O (9:1) as eluent, to give alkyne 31 (414.2 mg, 
80%) as yellowish oil. IR (NaCl) max (cm−1) 2977m, 2934m, 2231w, 1727s, 1687s, 1597w, 1574w, 1424m, 
1366s, 1219s, 1148s, 800m, 688m; 1H-NMR (300 MHz)  (ppm) 7.96 (1H, t, J = 1.6 Hz, H-2’), 7.85 (1H, 
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ddd, J = 7.7, 1.6, 1.6 Hz, H-6’), 7.56 (1H, ddd, J = 7.7, 1.6, 1.3 Hz, H-4’), 7.37 (1H, t, J = 7.7 Hz, H-5’), 2.59 
(3H, s, CH3), 2.47 (2H, t, J = 7.1 Hz, H-4), 2.40 (2H, t, J = 7.2 Hz, H-2), 1.89 (2H, quint, J = 7.2 Hz, H-3), 
1.45 (9H, s, C(CH3)3); 13C-NMR (75 MHz)  (ppm) 197.45 (CO), 172.40 (CO2tBu), 137.07 (C-3’), 135.86 (C-
4’), 131.54 (C-2’), 128.52 (C-5’), 127.22 (C-6’), 124.41 (C-1’), 90.36 (C-5), 80.32 (C-6), 80.27 (C(CH3)3), 
34.45 (C-2), 28.06 (C(CH3)3), 26.59 (CH3), 23.97 (C-3), 18.81 (C-4); ESI-HRMS m/z calcd. for C18H22NaO3 
[M+Na]+ 309.1467, found 309.1460. 
(E)-tert-Butyl 6-(3-(1-(hydroxyimino)ethyl)phenyl)hex-5-ynoate (32). Obtained as described above for the 
preparation of 3, starting from methyl ketone 31 (56.4 mg, 0.197 mmol), hydroxylamine chlorhydrate (55 
mg, 0.788 mmol), and dry pyridine (1.3 mL). Chromatography of the crude product, using hexane–Et2O 
(from 9:1 to 8:2) as eluent, afforded oxime 32 (54.9 mg, 92%) as an oil. IR (NaCl) max (cm−1) 3406m, 
2975m, 2933m, 2355w, 2219w, 1725s, 1594w, 1368m, 1313m, 1247m, 1149s, 1003m, 911w, 843w, 796w; 
1H-NMR (300 MHz)  (ppm) 8.26 (1H, br s, OH), 7.64 (1H, t, J = 1.5 Hz, H-2’), 7.55 (1H, ddd, J = 7.7, 1.5, 
1.5 Hz, H-6’), 7.39 (1H, ddd, J = 7.7, 1.5, 1.5 Hz, H-4’), 7.29 (1H, t, J = 7.7 Hz, H-5’), 2.47 (2H, t, J = 7.1 
Hz, H-4), 2.41 (2H, t, J = 7.2 Hz, H-2), 2.27 (3H, s, CH3), 1.89 (2H, quint, J = 7.1 Hz, H-3), 1.45 (9H, s, 
(C(CH3)3); 13C-NMR (75 MHz)  (ppm) 172.36 (CO2tBu), 155.51 (C=N), 136.60 (C-3’), 132.20 (C-4’), 
129.30 (C-2’), 128.38 (C-5’), 125.21 (C-6’), 124.11 (C-1’), 89.58 (C-5), 80.85 (C-6), 80.35 (C(CH3)3), 34.45 
(C-2), 28.13 (C(CH3)3), 24.12 (C-3), 18.84 (C-4), 11.96 (CH3); ESI-HRMS m/z calcd. for C18H23NNaO3 
[M+Na]+ 324.1576, found 324.1580. 
tert-Butyl 6-(3-((E)-1-(((2-((E)-2-methoxy-1-(methoxyimino)-2-oxoethyl)benzyl)oxy)imino)ethyl)phenyl) 
hex-5-ynoate (33). This compound was prepared following the procedure described above for compound 6 
starting from oxime 32 (40.3 mg, 0.134 mmol), benzyl bromide 16 (57.4 mg, 0.201 mmol), and Cs2CO3 
(65.5 mg, 0.201 mmol) in DMF (0.9 mL) and 15 h of reaction time. Chromatographic purification of the crude 
product, using hexane–Et2O (from 9:1 to 8:2) as eluent, afforded title compound 33 (57.3 mg, 84%) as a 
colorless oil. IR (NaCl) max (cm−1) 2972w, 2938w, 2339w, 1727s, 1590w, 1367m, 1219m, 1147m, 1069s, 
1019m, 946w, 861w, 787w; 1H-NMR (300 MHz)  (ppm) 7.62 (1H, t, J = 1.5 Hz, H-2’), 7.55–7.47 (2H, m, 
H-6’ and H-3’’), 7.46–7.33 (3H, m, H-5’’, H-4’’ and H-4’), 7.25 (1H, t, J = 7.7 Hz, H-5’), 7.18 (1H, dd, J = 
7.3, 1.4 Hz, H-6’’), 5.12 (2H, s, OCH2), 4.03 (3H, s, NOCH3), 3.82 (3H, s, CO2CH3), 2.46 (2H, t, J = 7.1 Hz, 
H-4), 2.40 (2H, t, J = 7.1 Hz, H-2), 2.18 (3H, s, CH3), 1.89 (2H, quint, J = 7.2 Hz, H-3), 1.46 (9H, s, 
C(CH3)3); 13C-NMR (75 MHz)  (ppm) 172.49 (CO2tBu), 163.28 (CO2CH3), 154.39 (CH3CN), 149.77 (C=N), 
136.51 (C-1’’), 136.17 (C-3’), 132.12 (C-6’), 129.36 (C-2’), 128.71 (C-4’), 128.60 (C-5’’), 128.50 (C-6’’), 
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128.24 (C-5’), 127.63 (C-4’’), 125.34 (C-3’’ and C-2’’), 123.92 (C-1’), 89.43 (C-5), 80.92 (C-6), 80.29 
(C(CH3)3), 74.67 (OCH2), 63.77 (NOCH3), 52.87 (CO2CH3), 34.44 (C-2), 28.10 (C(CH3)3), 24.05 (C-3), 
18.86 (C-4), 12.63 (CH3); ESI-HRMS (m/z calcd. for C29H34N2NaO6 [M+Na]+ 529.2315, found 529.2319. 
6-(3-((E)-1-(((2-((E)-2-Methoxy-1-(methoxyimino)-2-oxoethyl)benzyl)oxy)imino)ethyl) phenyl)hex-5-ynoic 
acid (hapten TFt). Hydrolysis of the tert-butyl ester of 33 (49.8 mg, 0.098 mmol) with formic acid (2.0 mL) 
under the same conditions reported above for 8 afforded, after chromatographic purification with CHCl3 as 
eluent, hapten TFt (40.8 mg, 92%) as a colorless oil. IR (NaCl) max (cm−1) 3500-2700s (broad) 2942m, 
2246w, 1726s, 1590w, 1437m, 1318m, 1069s, 1019s, 910m, 732s; 1H-NMR (300 MHz)  (ppm) 7.62 (1H, t, 
J = 1.5 Hz, H-2’), 7.55–7.47 (2H, m, H-6’ and H-3’’), 7.46–7.33 (3H, m, H-5’’, H-4’’, and H-4’), 7.25 (1H, t, J 
= 7.7 Hz, H-5’), 7.18 (1H, dd, J = 7.3, 1.4 Hz, H-6’’), 5.12 (2H, s, OCH2), 4.03 (3H, s, NOCH3), 3.81 (3H, s, 
CO2CH3), 2.56 (2H, t, J = 7.1 Hz, H-4), 2.51 (2H, t, J = 7.2 Hz, H-2), 2.18 (3H, s, CH3), 1.94 (2H, quint, J = 
7.2 Hz, H-3); 13C-NMR (75 MHz)  (ppm) 178.4 (CO2H), 163.3 (CO2CH3), 154.4 (CH3C=N), 149.6 (C=N), 
136.5 (C-1’’), 136.2 (C-3’), 132.1 (C-6’), 129.7 (C-2’’), 129.4 (C-2’), 129.2 (C-5’’), 128.7 (C-4’), 128.5 (C-6’’), 
128.2 (C-5’), 127.6 (C-4’’), 125.4 (C-3’’), 123.8 (C-1’), 89.9 (C-5), 81.3 (C-6), 74.7 (OCH2), 63.9 (NOCH3), 
52.9 (CO2CH3), 32.7 (C-2), 23.5 (C-3), 18.8 (C-4), 12.6 (CH3); ESI-HRMS m/z calcd for C25H26N2NaO6 
[M+Na]+ 473.1689, found 473.1687; UV (100 mM sodium phosphate buffer, pH 7.4) Є (280 nm) 2.67 mM−1 
cm−1. 
tert-Butyl 6-(3-((E)-1-(((2-((E)-2-methoxy-1-(methoxyimino)-2-oxoethyl)benzyl)oxy)imino)ethyl)phenyl) 
hexanoate (34). Alkyne 33 (62.5 mg, 0.123 mmol) was hydrogenated as described above for the 
preparation of 7 using Rh(PPh3)3Cl (5.7 mg, 0.006 mmol) and THF (2.7 mL). Purification of the crude 
product by chromatography with hexane–Et2O (8:2) as eluent gave title compound 34 (57.1 mg, 91%) as a 
colorless oil. IR (NaCl) max (cm−1) 2976s, 2936s, 2858s, 1731s, 1592w, 1485m, 1437s, 1391m, 1367s, 
1218s, 1155s, 1069s, 1020s, 957s, 898m, 790m; 1H-NMR (300 MHz)  (ppm) 7.51 (1H, dd, J = 7.4, 1.3 Hz, 
H-3’’), 7.46–7.33 (4H, m, H-2’, H-4’, H-4’’ and H-5’’), 7.25 (1H, t, J = 7.8 Hz, H-5’), 7.21–7.12 (2H, m, H-6’’ 
and H-6’), 5.13 (2H, s, OCH2), 4.03 (3H, s, NOCH3), 3.81 (3H, s, CO2CH3), 2.62 (2H, t, J = 7.5 Hz, H-6), 
2.21 (2H, t, J = 7.5 Hz, H-2), 2.20 (3H, s, CH3), 1.69–1.55 (4H, m, H-3 and H-5), 1.43 (9H, s, C(CH3)3), 
1.41–1.32 (2H, m, H-4); 13C-NMR (75 MHz)  (ppm) 173.14 (CO2tBu), 163.28 (CO2CH3), 155.29 (CH3CN), 
149.58 (C=N), 142.63 (C-1’), 136.46 (C-1’’), 136.24 (C-3’), 129.73 (C-2’’), 129.38 (C-6’), 129.16 (C-6’’), 
128.67 (C-3’’), 128.49 (C-5’’), 128.23 (C-5’), 127.53 (C-4’’), 126.07 (C-2’), 123.58 (C-4’), 79.92 (C(CH3)3), 
74.52 (OCH2), 63.74 (NOCH3), 52.82 (CO2CH3), 35.62 (C-6), 35.50 (C-2), 31.06 (C-5), 28.68 (C-4), 28.05 
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(C(CH3)3), 24.93 (C-3), 12.86 (CH3); ESI-HRMS m/z calcd. for C29H38N2NaO6 [M+Na]+ 533.2628, found 
533.2630. 
6-(3-((E)-1-(((2-((E)-2-Methoxy-1-(methoxyimino)-2-oxoethyl)benzyl)oxy)imino)ethyl)phenyl) hexanoic 
acid (hapten TFf). Hydrolysis of the tert-butyl ester of 34 (26.5 mg, 0.052 mmol) with formic acid (1.0 mL) 
under the same conditions reported above for 8 afforded, after chromatographic purification with CHCl3 as 
eluent, hapten TFf (21.4 mg, 91%) as a white solid. Mp 85–87 °C (crystallized from hexane–benzene); IR 
(KBr) max (cm−1) 3500-2700 (broad), 3060m, 2933s, 1717s, 1595w, 1436m, 1298s, 1066s, 1010s, 932s; 
1H-NMR (300 MHz)  (ppm)7.50 (1H, dd, J = 7.4, 1.3 Hz, H-3’’), 7.46–7.33 (4H, m, H-2’, H-4’, H-4’’ and 
H-5’’), 7.25 (1H, t, J = 7.7 Hz, H-5’), 7.21–7.14 (2H, m, H-6’’ and H-6’), 5.13 (2H, s, OCH2), 4.03 (3H, s, 
NOCH3), 3.81 (3H, s, CO2CH3), 2.62 (2H, t, J = 7.5 Hz, H-6), 2.35 (2H, t, J = 7.5 Hz, H-2), 2.20 (3H, s, 
CH3), 1.73–1.58 (4H, m, H-3 and H-5), 1.43–1.33 (2H, m, H-4); 13C-NMR (75 MHz)  (ppm) 178.9 (CO2H), 
163.3 (CO2CH3), 155.3 (CH3C=N), 149.6 (C=N), 142.5 (C-1’), 136.5 (C-1’’), 136.2 (C-3’), 129.7 (C-2’’), 
129.3 (C-6’), 129.2 (C-6’’), 128.7 (C-3’’), 128.5 (C-5’’), 128.3 (C-5’), 127.6 (C-4’’), 126.1 (C-2’), 123.7 (C-
4’), 74.6 (OCH2), 63.8 (NOCH3), 52.9 (CO2CH3), 35.6 (C-6), 33.8 (C-2), 31.0 (C-5), 28.6 (C-4), 24.5 (C-3), 
12.9 (CH3); ESI-HRMS m/z calcd for C25H38N2NaO6 [M+Na]+ 477.2002, found 477.2005; UV (100 mM 





















35 TFc-H CF3 H 90%
36 TFc-Et CF3 C2H5 98%
37 TFf-H H CH3 64%
38 TFf-NO2 NO2 CH3 84%


















Figure S7. Synthesis of trifloxystrobin analogues 
2.1. Synthesis of TFc-H, TFc-Et, TFf-H and TFf-NO2,. 
General procedure. A mixture of the oxime 35-38 (1 mmol), benzyl bromide 16 (1 mmol), and anhydrous 
Cs2CO3 (1.5 mmol) in anhydrous DMF (3.8 mL) was stirred at room temperature under nitrogen until TLC 
showed completion of reaction (approx. 3-4 hours) at which time the reaction mixture was poured into water 
and worked up as usual using EtOAc to extract. Chromatography of the residue left after evaporation of the 
solvent, using hexane–Et2O (9:1 to 8:2) as eluent, afforded the corresponding trifloxystrobin analogue. 
Physical and spectroscopic data of analogue TFc-H. An oil [Lit.11 no data given]; IR (NaCl) max (cm– 1) 
3065w, 2943m, 2820w, 1728s, 1585w, 1437m, 1350m, 1322s, 1278m, 1219s, 1127s, 1079s, 1019s, 957m, 
766m, 668m; 1H NMR (300 MHz)  8.06 (1H, s, HC=), 7.81 (1H, s, H–2’), 7.71 (1H, d, J = 7.8 Hz, H–6’), 
7.60 (1H, d, J = 7.8 Hz, H–4’), 7.51–7.35 (4H, m, H6, H–5’, H-5 and H–4), 7.19 (1H, dd, J = 7.3, 1.5 Hz, 
H–3), 5.12 (2H, s, OCH2), 4.02 (3H, s, NOCH3), 3.84 (3H, s, CO2CH3); 13C NMR (75 MHz)  163.31 
(CO2CH3), 149.60 (HCN), 147.70 (C=N), 135.60 (C–2), 132.93 (C–1’), 130.22 (C–3’, c, J = 32.5 Hz), 
130.21 (C–6’), 130.20 (C–1), 129.43 (C–6), 129.13 (C–5’), 128.79 (C–5), 128.54 (C–3), 127.89 (C–4), 
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126.30 (C–4’, c, J = 3.8 Hz), 123.70 (C–2’, c, J = 3.8 Hz), 115.12 (CF3, c, J = 272.0 Hz), 74.89 (OCH2), 
63.78 (NOCH3), 52.90 (CO2CH3); ESI-HRMS m/z calcd. for C19H18F3N2O4 [M+H]+ 395.1219, found 
395.1222. 
Physical and spectroscopic data of analogue TFc-Et. IR (NaCl) max (cm– 1) 2978w, 2934w, 1722m, 
1630w, 1558w, 1432w, 1323m, 1295m, 1213m, 1170m, 1126s, 1071s, 1017s, 957w; 1H NMR (300 MHz)  
7.86 (1H, s, H–2’), 7.77 (1H, d, J = 7.5 Hz, H–6’), 7.59 (1H, d, J = 7.5 Hz, H–4’), 7.51 (1H, dd, J = 7.6, 1.2 
Hz, H–6), 7.47 (1H, t, J = 7.5 Hz, H–5’), 7.43 (1H, ddd, J = 7.6, 7.5, 1.5 Hz, H–5), 7.38 (1H, ddd, J = 7.5, 
7.5, 1.2 Hz, H–4), 7.19 (1H, dd, J = 7.5, 1.5 Hz, H–3), 5.15 (2H, s, OCH2), 4.04 (3H, s, NOCH3), 3.82 (3H, 
s, CO2CH3), 2.74 (2H, c, J = 7.6 Hz, CH2), 1.11 (3H, t, J = 7.6 Hz, CH3); 13C NMR (75 MHz)  163.29 
(CO2CH3), 158.64 (CH2CN), 149.42 (C=N), 136.20 (C–2), 136.01 (C-1’), 130.83 (C–3’, c, J = 32.5 Hz), 
129.68 (C–1), 129.50 (C–6’), 129.37 (C–6), 128.87 (C–5’), 128.70 (C–5), 128.46 (C–3), 127.70 (C–4), 
125.50 (C–4’, c, J = 3.8 Hz), 123.89 (CF3, c, J = 272.2 Hz), 123.03 (C–2’, c, J = 3.8 Hz), 74.70 (OCH2), 
63.80 (NOCH3), 52.89 (CO2CH3), 19.81 (CH2), 10.97 (CH3); ESI-HRMS m/z calcd. for C21H21F3N2NaO4 
[M+Na]+ 445.1351, found 445.1354. 
Physical and spectroscopic data of analogue TFf-H. Mp 82–83 ºC (Crystallized from hexane–benzene) 
[Lit.12 69-71ºC]; IR (KBr) max (cm– 1) 3049w, 2940w, 1739s, 1612w, 1585m, 1492m, 1438s, 1368m, 1302s, 
1226s, 1208m, 1115w, 1067s, 1034s, 1009s, 928s, 898s, 696m; 1H NMR (300 MHz)  7.62–7.56 (2H, m, 
H–6’ and H–2’), 7.50 (1H, dd, J = 7.4, 1.3 Hz, H6), 7.46–7.31 (5H, m, H–4, H–5, H–4’, H–5’ and H-3’), 
7.19 (1H, dd, J = 7.4, 1.3 Hz, H–3), 5.12 (2H, s, OCH2), 4.03 (3H, s, NOCH3), 3.81 (3H, s, CO2CH3), 2.21 
(3H, s, CH3); 13C NMR (75 MHz)  161.25 (CO2CH3), 152.39 (CH3CN), 149.61 (C=N), 136.48 (C–2), 136.28 
(C–1’), 129.36 (C–4’), 128.75 (C–6), 128.50 (C–4), 128.33 (C–3’ and C–5’), 128.21 (C–1), 127.60 (C–5), 
126.13 (C–2’ and c–6’), 124.05 (C–3), 74.68 (OCH2), 63.77 (NOCH3), 52.86 (CO2CH3), 12.73 (CH3); 
ESI-HRMS m/z calcd. for C19H20N2NaO4 [M+Na]+ 363.1321, found 363.1321. 
Physical and spectroscopic data of analogue TFf-NO2. Mp 126–128 ºC (Crystallized from hexane–
benzene) [Lit.13 solid, no mp given]; IR (KBr) max (cm– 1) 2956w, 2934w, 2863w, 1733s, 1612w, 1530s, 
1435m, 1350s, 1301m, 1222m, 1070s, 1003s, 916m, 774m, 737m, 681m; 1H NMR (300 MHz)  8.45 (1H, t, 
J = 2.0 Hz, H–2’), 8.18 (1H, ddd, J = 8.0, 2.0, 1.0 Hz, H–4’), 7.95 (1H, ddd, J = 8.0, 2.0, 1.0 Hz, H–6’), 7.51 
(1H, t, J = 8.0 Hz, H–5’), 7.49 (1H, dd, J = 7.5, 1.5 Hz, H–6), 7.45 (1H, ddd, J = 7.5, 7.4, 1.2 Hz, H–5), 7.39 
(1H, ddd, J = 7.5, 7.4, 1.5 Hz, H–4), 7.19 (1H, dd, J = 7.4, 1.2 Hz, H-3), 5.16 (2H, s, OCH2), 4.04 (3H, s, 
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NOCH3), 3.83 (3H, s, CO2CH3), 2.25 (3H, s, CH3); 13C NMR (75 MHz)  163.29 (CO2CH3), 152.75 
(CH3CN), 149.51 (C=N), 148.34 (C–3’), 138.08 (C–2), 135.76 (C–1’), 131.70 (C–6’), 129.85 (C–1), 129.42 
(C5’), 129.26 (C–6), 128.82 (C–5), 128.55 (C–3), 127.87 (C–4), 123.63 (C4’), 120.96 (C–2’), 75.13 
(OCH2), 63.82 (NOCH3), 52.92 (CO2CH3), 12.40 (CH3); ESI-HRMS m/z calcd. for C19H21N3NaO6 [M+Na]+ 
408.1172, found 408.1171. 
2.2. Synthesis of TFf-NH2. 
A mixture of compound TFf–NO2 (24 mg, 0.062 mmol) and SnCl2 (59 mg, 0.310 mmol) in EtOAc (2 mL) 
was stirred under nitrogen at 50ºC overnight. The mixture was then cooled to room temperature, diluted with 
water and extracted with EtOAc. The combined organic layers were washed with 10% aqueous NaOH 
solution and brine and dried over anhydrous Na2SO4. Chromatographic purification of the residue left after 
evaporation of the solvent, using hexane-EtOAc 8:2 as eluent, led to compound TFf–NH2 (19.1 mg, 87%) as 
an oil. IR (NaCl) max (cm– 1) 3459w, 3374w, 2938w, 1727s, 1624w, 1580w, 1439w, 1368m, 1219m, 1069s, 
1017s, 957w, 861w, 781m; 1H NMR (300 MHz)   7.51 (1H, dd, J = 7.5, 1.3 Hz, H-6), 7.42 (1H, ddd, J = 
7.5, 7.5, 1.5 Hz, H–5), 7.38 (1H, ddd, J = 7.5, 7.5, 1.3 Hz, H–4), 7.19 (1H, dd, J = 7.5, 1.5 Hz, H–3), 7.12 
(1H, t, J = 8.0 Hz, H–5’), 6.97–6.92 (2H, m, H–2’ and H–6’), 6.67 (1H, ddd, J = 8.0, 2.3, 1.0 Hz, H-4’), 5.10 
(2H, s, OCH2), 4.03 (3H, s, NOCH3), 3.81 (3H, s, CO2CH3), 2.17 (3H, s, CH3); 13C NMR (75 MHz)  163.72 
(CO2CH3), 155.32 (CH3CN), 149.78 (C=N), 146.78 (C–3’), 137.92 (C–2), 136.76 (C–1’), 129.38 (C–1), 
129.35 (C–6), 129.22 (C–5’), 128.73 (C–5), 128.45 (C3), 127.51 (C–4), 116.68 (C–6’), 115.95 (C–4’), 
112.53 (C–2’), 74.47 (OCH2), 63.72 (NOCH3), 52.85 (CO2CH3), 12.82 (CH3); ESI-HRMS m/z calcd. for 












Number of wells Number of stabilized 
hybridomas Seededb Positivec Competitived 
BSA–TFa #1e 53 576 6 1 1 
#2e 78 960 13 6 3 
BSA–TFb #1 98 864 23 6 1 
#2 73 480 4 0 0 
#3 65 960 56 3 0 
#4 100 672 23 4 1 
BSA–TFc #1f 95 960 200 10 3 
BSA–TFe #1 46 672 16 3 0 
#2 49 672 31 7 2 
#3 100 672 107 3 2 
#4 69 960 453 6 0 
BSA–TFo #1e 100 1152 57 14 4 
#2e 59 864 5 0 0 
BSA–TFf #1e 67 1344 38 5 1 
#2e 59 1056 30 8 2 
BSA–TFt #1 61 768 120 10 1 
#2 64 864 635 4 3 
#3e 78 1440 644 10 4 
a Percentage of seeded wells showing hybrid cell growth by visual inspection 11 days after fusion. b 96-well culture plates 
were seeded at 1.5 × 105 splenocytes per well. c The supernatant afforded Amax values higher than 0.5 in a control 
experiment without free analyte. d Amax was reduced more than 50% with 100 nM trifloxystrobin. e This cell fusion was 
carried with a pool of mixed splenocytes from two mice. f One mouse died and the splenocytes of the other three mice 
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